147 results on '"Beccaria K"'
Search Results
2. Ré-actualisation d’une série de 30 tumeurs cérébrales gliales/glio-neuronales du nourrisson : paysage histomoléculaire et proposition de critères diagnostiques
- Author
-
Tauziede-Espariat, A., primary, Beccaria, K., additional, Dangouloff-Ros, V., additional, Saffroy, R., additional, Hasty, L., additional, Metais, A., additional, Chretien, F., additional, Blauwblomme, T., additional, Puget, S., additional, Boddaert, N., additional, and Varlet, P., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Arterial spin labelling: predictive role in surgical bleeding of paediatric optic pathway gliomas
- Author
-
Ramond, D., primary, Puget, S., additional, Varlet, P., additional, Vergnaud, E., additional, Montmayeur, J., additional, Purcell, Y., additional, Beccaria, K., additional, Blauwblomme, T., additional, Boddaert, N., additional, and Dangouloff-Ros, V., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Chapitre 103 - Pathologies neurochirurgicales
- Author
-
Puget, S. and Beccaria, K.
- Published
- 2024
- Full Text
- View/download PDF
5. Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?
- Author
-
Lobon-Iglesias, M. J., Giraud, G., Castel, D., Philippe, C., Debily, M. A., Briandet, C., Fouyssac, F., de Carli, E., Dufour, C., Valteau-Couanet, D., Sainte-Rose, C., Blauwblomme, T., Beccaria, K., Zerah, M., Puget, S., Calmon, R., Boddaert, N., Bolle, S., Varlet, P., and Grill, J.
- Published
- 2018
- Full Text
- View/download PDF
6. Infantile hydrocephalus: A retrospective cohort of 467 patients from a single center
- Author
-
Caudron, Y., primary, Beccaria, K., additional, Bourgeois, M., additional, Benichi, S., additional, Guida, L., additional, James, S., additional, Paternoster, G., additional, and Blauwblomme, T., additional
- Published
- 2022
- Full Text
- View/download PDF
7. Hippocampal Sparing Radiotherapy in adults with Primary Brain Tumors: A comparative planning and dosimetric study using IMPT, IMRT and 3DCRT
- Author
-
Aka, P, Taylor, R, Hugtenburg, R, Lambert, J, Powell, J, Bevolo, T, Gao, M, Gondi, V, Hartsell, W.H, Bolsi, A, Beer, J, Belosi, M.F, Siewert, D, Lomax, A.J, Weber, D.C, Huang, Y.J, Huang, C.C, Chao, P.J, Liu, C, Shang, H, Ding, X, Wang, Y, Mammar, H, Froelich, Sébastien, Alapetite, Claire, Bolle, Stéphanie, Calugaru, Valentin, Feuvret, Loic, Helfre, Sylvie, Champion, Laurence, Goudjil, Farid, Dendal, Remi, Engelholm, S.A, Munck Af Rosenschold, P, Kristensen, I, Smulders, B, Muhic, A, Alkner, S, Jacob, E, Engelholm, S, Aljabab, S, Lui, A, Wong, T, Liao, J, Laramore, G, Parvathaneni, U, Kharouta, M, Pidikiti, R, Jesseph, F, Smith, M, Dobbins, D, Mattson, D, Choi, S, Mansur, D, Machtay, M, Bhatt, A, Lütgendorf-Caucig, C, Dunavölgyi, R, Georg, P, Perpar, A, Fussl, C, Konstantinovic, R, Ulrike, M, Piero, F, Eugen, H, Vidal, M, Gerard, A, Barnel, C, Maneval, D, Herault, J, Claren, A, Doyen, J, Dendale, R, Toutee, A, Pasquie, I, Goudjil, F, Lumbroso Lerouic, L, Levy, C, Desjardins, L, Cassoux, N, Elisei, G, Pella, A, Calvi, G, Ricotti, R, Tagaste, B, Valvo, F, Ciocca, M, Via, R, Mastella, E, Baroni, G, Saotome, N, Yonai, S, Makishima, H, Hara, Y, Inaniwa, T, Sakama, M, Kanematsu, N, Tsuji, H, Furukawa, T, Shirai, T, Sauerwein, W, Finger, P.T, Gallie, B, Gavrylyuk, Y, Thariat, J, Salleron, J, Maschi, C, Fevrier, E, Caujolle, J.P, Hofverberg, P, Angellier, G, Peyrichon, M.L, Breneman, J, Esslinger, H, Pater, L, Vatner, R, Habrand, J.L, Stefan, D, Lesueur, P, Kao, W, Véla, A, Geffrelot, J, Tessonnier, T, Balosso, J, Mahé, M.A, Lim, P.S, Rompokos, V, Chang, Y.C, Royle, G, Gaze, M, Gains, J, Vennarini, S, Francesco, F, Rombi, B, Amichetti, M, Schwarz, M, Lorentini, S, Mee, T, Burnet, N.G, Crellin, A, Kirkby, N.F, Smith, E, Kirkby, K.J, Roggio, M, Buwenge, M, Melchionda, F, Ammendolia, I, Ronchi, L, Cammelli, S, Morganti, A.G, Youn, S.H, Kim, J.Y, Park, H.J, Shin, S.H, Lee, S.H, Hong, E.K, Czerska, K, Winczura, P, Wejs-Maternik, J, Blukis, A, Antonowicz-Szydlowska, M, Rucinski, A, Olko, P, Badzio, A, Kopec, R, Franceschini, D, Cozzi, L, De Rose, F, Meattini, I, Fogliata, A, Cozzi, S, Becherini, C, Tomatis, S, Livi, L, Scorsetti, M, Garda, A, Fattahi, S, Michel, A, Mutter, R, Yan, E, Park, S, Corbin, K, Giap, H, LAM, W.W, Geng, H, Tang, K.K, Lee, T.Y, Kong, C.W, Yang, B, Chiu, T.L, Cheung, K.Y, Yu, S.K, Ma, M, Gao, X, Zhao, Z, Zhao, B, Mullikin, T, Routman, D, Yu, J, Greco, K, Fagundes, M, Shan, J, Daniels, T, Rule, W, DeWees, T, Hu, Y, Bues, M, Sio, T, Liu, W, chenbin, L, yuehu, P, yuenan, W, Bai, Y, Gao, X.S, Zhao, Z.L, Ma, M.W, Ren, X.Y, Salem, A, Woolf, D, Aznar, M, Azadeh, A, Eccles, C, Charlwood, F, Faivre-Finn, C, Teoh, S, Fiorini, F, George, B, Vallis, K, Van den Heuvel, F, Huang, E.Y, Juang, P.J, Pan, S, Hawkins, M, Clarke, M, Lowe, M, Radhakrishna, G, Schaub, S, Bowen, S, Nyflot, M, Chapman, T, Apisarnthanarax, S, Vitek, P, Kubes, J, Vondracek, V, Vinakurau, S, Zamecnik, L, Vitolo, V, Barcellini, A, Brugnatelli, S, Cobianchi, L, Vanoli, A, Fossati, P, Facoetti, A, Dionigi, P, Orecchia, R, Iannalfi, A, Vischioni, B, Ronchi, S, D’Ippolito, E, Petrucci, R, Yamaguchi, H, Honda, M, Hamada, K, Todate, Y, Seto, I, Suzuki, M, Wada, H, Murakami, M, Yu, Z, Zheng, W, Lien-Chun, L, Zhengshan, H, Qing, Z, Jiade, L, Guoliang, J, Fiore, M.R, D'Ippolito, E, Fukumitsu, N, Hayakawa, T, Yamashita, T, Mima, M, Demizu, Y, Suzuki, T, Soejima, T, Hartsell, W, Collins, S, Casablanca, V, Mihalcik, S, Brennan, E, Van Nispen, A, Corbett, A, Mohammed, N, Lee, P, van Nispen, A, Liang, Y.S, Mein, S, Kopp, B, Choi, K, Haberer, T, Debus, J, Abdollahi, A, Mairani, A, Ogino, H, Iwata, H, Hashimoto, S, Nakajima, K, Hattori, Y, Nomura, K, Shibamoto, Y, Li, P, Wu, S, Deng, L, Zhang, G, Zhang, Q, Fu, S, Yang, Z, Zhang, Y, Sasaki, R, Okimoto, T, Akasaka, H, Miyawaki, D, Yoshida, K, Wang, T, Komatsu, S, Fukumoto, T, Shuang, W, Xin, C, zhengshan, H, Shen, F, Vorobyov, N, Andreev, G, Martynova, N, Lyubinsky, A, Kubasov, A, Chen, J, Ma, N, Lu, Y, Zhao, J, Shahnazi, K, Lu, J, Jiang, G, Mao, J, Walser, M, Bojaxhiu, B, Kawashiro, S, Tran, S, Pica, A, Bachtiary, B, Weber, D, Gaito, S, Abravan, A, Richardson, J, Colaco, R, Saunders, D, Brennan, B, Petersen, I, Ahmed, S, Laack, N, Mizoe, J.E, Iizumi, T, Minohara, S, Kusano, Y, Matsuzaki, Y, Tsuchida, K, Serizawa, I, Yoshida, D, Katoh, H, Sakurai, H, Tujii, H, Kim, T.H, Park, J.W, Bo Hyun, K, Hyunjung, K, Sung Ho, M, Sang Soo, K, Sang Myung, W, Young-Hwan, K, Woo Jin, L, Dae Yong, K, Hong, Z, Wang, Z, Koroulakis, A, Molitoris, J, Kaiser, A, Hanna, N, Jiang, Y, Regine, W, DeCesaris, C.M, Choi, J.I, Carr, S.R, Burrows, W.M, Regine, W.F, Simone, C.B, Aihara, T, Hiratsuka, J, Kamitani, N, Higashino, M, Kawata, R, Kumada, H, Ono, K, Chou, Y.C, Dippolito, E, Bonora, M, Alterio, D, Gandini, S, Jereczeck, B.A, Kelly, C, Dobeson, C, Iqbal, S, Chatterjee, S, Hague, C, Li, T, Lin, A, Lukens, J, Slevin, N, Thomson, D, van Herk, M, West, C, Teo, K, Jeans, E, Manzar, G, Patel, S, Ma, D, Lester, S, Foote, R, Friborg, J, Jensen, K, Hansen, C.R, Andersen, E, Andersen, M, Eriksen, J.G, Johansen, J, Overgaard, J, Grau, C, Dědečková, K, Vítek, P, Ondrová, B, Sláviková, S, Zapletalová, S, Zapletal, R, Vondráček, V, Rotnáglová, E, Kwanghyun, J, Woojin, L, Dongryul, O, Yong Chan, A, Paudel, N, Schmidt, S, Ruckman, M, Gans, S, Stauffer, M, Helenowski, I, Patel, U, Samant, S, Gentile, M, Damico, N, Yao, M, Shuja, M, Routman, D.M, Foote, R.L, Garces, Y.I, Neben-Wittich, M.A, Patel, S.H, McGee, L.A, Harmsen, W.S, Ma, D.J, Sommat, K, Tong, A.K.T, Hu, J, Ong, A.L.K, Wang, F, Sin, S.Y, Wee, T.S, Tan, W.K, Fong, K.W, Soong, Y.L, Wallace, N, Fredericks, S, Fitzgerald, T, Vernimmen, F, Petringa, G, Cirrone, P, Agosteo, S, Attili, A, Cammarata, F.P, Cuttone, G, Conte, V, La Tessa, C, Manti, L, Rosenfeld, A, Lojacono, P.A, Hennings, F, Fattori, G, Peroni, M, Lomax, A, Hrbacek, J, Nguyen, H.G, Bach Cuadra, M, Sznitman, R, Schalenbourg, A, Pflaeger, A, Weber, A, Seidel, S, Stark, R, Heufelder, J, Mailhot Vega, R, Bradley, J, Lockney, N, Macdonald, S, Liang, X, Mazal, A, Mendenhall, N, Sher, D, Korreman, S.S, Andreasen, S, Petersen, J.B, Offersen, B.V, Gergelis, K, Jethwa, K, Whitaker, T, Shiraishi, S, Shumway, D, Press, R, Shelton, J, Zhang, C, Dang, Q, Tian, S, Shu, T, Seldon, C, Jani, A, Zhou, J, McDonald, M, Gort, E, Beukema, J.C, Spijkerman-Bergsma, M.J, Both, S, Langendijk, J.A, Matysiak, W.P, Brouwer, C.L, Baba, K, Numajiri, H, Murofushi, K, Oshiro, Y, Mizumoto, M, Onishi, K, Nonaka, T, Ishikawa, H, Okumura, T, Dominietto, M, Adam, K, Ahlhelm, F.J, Safai, S, Abdul-Jabbar, L, Song, J, Tseng, Y. D, Rockhill, J, Fink, J, Chang, L, Halasz, L. M, Guntrum, F, Steinmeier, T, Nagaraja, S, Jazmati, D, Geismar, D, Timmermann, B, Plaude, S, Lynch, C, Petras, K, Chang, J, Grimm, S, Lukas, R, Kumthekar, P, Merrell, R, Kalapurakal, J, Gross, J, Hoppe, B, Simone, C, Nichols, R.C, Pham, D, Mohindra, P, Chon, B, Morris, C, Li, Z, Flampouri, S, Powell, J.R, Murray, L, Burnet, N, Fernandez, S, Lingard, Z, McParland, L, O’Hara, D, Whitfield, G, Short, S.C, Guan, X, Gao, J, Hu, W, Yang, J, Xing, X, Hu, C, Kong, L, Zou, Z, Thomas, H, Sasidharan, B.K, Rengan, R, Zeng, J, Busold, S, Heese, J, Cerello, P, Bottura, L, Felcini, E, Ferrero, V, Monaco, V, Pennazio, F, de Rijk, G, Chang, H, KyungDon, C, Byunghun, H, Gyuseong, C, Chilukuri, S, Jalali, R, Panda, P.K, Korn, G, Larosa, G, Russo, A, Schillaci, F, Scuderi, V, Margarone, D, Fredén, E, Almhagen, E, Mejaddam, Y, Siegbahn, A, Guardiola, C, Gómez, F, Prieto-Pena, J, Fleta, C, De Marzi, L, Prezado, Y, Kabolizadeh, P, Reitemeier, P, Navin, M, Hamstra, D, Anderson, J, Stevens, C, Bartolucci, L, Adrien, C, Lejars, M, Vaillant, M, Fourquet, A, Robillard, M, Costa, E, Kirova, Y, Kolano, A.M, Degiovanni, A, Farr, J.B, Kundel, S, Pinto, M, Kurichiyanil, N, Würl, M, Englbrecht, F, Hillbrand, M, Schreiber, J, Parodi, K, Kurup, A, Magliari, A, Perez, J, Masui, S, Asano, T, Owen, H, Burt, G, Apsimon, R, Pitman, S, Popovici, M.A, Vasilache, R, Safavi-Naeini, M, Chacon, A, Howell, N, Middleton, R.J, Fraser, B, Guatelli, S, Rendina, L, Matsufuji, N, Gregoire, M.C, Sikora, K, Pettingell, J, Crocker, M, Saplaouras, A, Snijders, A, Mao, J.H, Nakamura, K, Bin, J, Gonsalves, A, Mao, H.S, Steinke, S, Roach, M, Leemans, W, Blakely, E, Takayama, K, Tan, T.S, Wee, J.T.S, Tuan, J.K.L, Wang, M.L.C, Quah, J.S.H, Tay, N.C.W, Lee, J.C.L, Lim, J.K.H, Oei, A.A, Tan, J.M, Park, S.Y, Chow, W.W.L, Omar, Y.B, Chew, P.G, Taylor, P, Lee, J, Tsurudome, T, Hirabayashi, M, Tsutsui, H, Yoshida, J, Takahashi, N, Kamiguchi, N, Hashimoto, A, Tachikawa, T, Mikami, Y, Kumata, Y, Wang, M, Chua, E.T, Wee, J, Wong, F.Y, Tuan, J, Master, Z, Wong, S, Welsh, J, Hentz, C, Pankuch, M, DeJongh, F, Xia, Y, Aitkenhead, A.H, Appleby, R, Merchant, M.J, MacKay, R.I, Young, H, Hughes, V, Alsulimane, M, Barajas, C.A, Taylor, J, Casse, G, Omar, A, Burdin, S, Boon, C, Lester, J, Thomas, A.J, Khan, A, Huthart, L, Leaver, K, Snell, J, Warlow, A, Burigo, L.N, Oborn, B, Belosi, F, Fredh, A, van de Water, S, Schneider, T, Patriarca, A, Bergs, J, Hierso, E, Hirayama, R, Martínez-Rovira, I, Seksek, O, Shirato, H, Nakamura, T, Ogino, T, Akimoto, T, Tamamura, H, Nishimoto, N, Proton-Net, G, Shimizu, S, Fabiano, S, Bangert, M, Guckenberger, M, Unkelbach, J, Mcauley, G, Teran, A, Slater, J, Wroe, A, Boon, I, Clorley, J, Owen, K, Oliver, T, Cicchetti, A, Ballarini, F, Rancati, T, Carrara, M, Zaffaroni, N, Bezawy, R. El, Carante, M, Valdagni, R, Faccini, R, Forte, G.I, Dhinsey, S, Greenshaw, T, Parsons, J, Welsch, C, Stock, M, Grevillot, L, Kragl, G, Carlino, A, Martino, G, Hug, E, Arya, H, Chirayath, V.A, Jin, M, Weiss, A.H, Glass, G.A, Chi, Y, Kaplan, L.P, Perez, R.A, Vestergaard, A, Gittings, E, Stamper, J, Beltran, C, Mark, P, Furutani, K, McAuley, G, Gordon, J, Boisseau, P, Dart, A, Nett, W, Kollipara, S, Grossmann, M, Actis, O, Diete, W, Rudolf, D, Klein, H.U, Kramert, R, Meer, D, Venkataraman, C, Waterstradt, T, Hérault, J, Bergerot, J.M, Hsi, W.C, Zhou, R, Zhang, X, Yang, F, Yinxiangzi, S, Sun, J, Li, X, Zhiling, C, Yuehu, P, Mengya, G, Haiyun, K, Qi, L, Zhentang, Z, Lin, Y.H, Tan, H.Q, Tan, L.K.R, Ang, K.W, Xiufang, L, Milkowski, K, Pang, D, Jones, M, Mizota, M, Tsunashima, Y, Himukai, T, Ogata, R, Uno, T, Ouyang, L, Jia, B, Li, D, Paul, K, Pullia, M, Savazzi, S, Lante, V, Foglio, S, Donetti, M, Falbo, L, Casalegno, L, Rousseau, M, Shinomiya, K, Yazawa, T, Iseki, Y, Kanai, Y, Hirata, Y, Powers, J, Solovev, A, Chernukha, A, Saburov, V, Shegai, P, Ivanov, S, Kaprin, A, Stolarczyk, L, Mojżeszek, N, Van Hoey, O, Farah, J, Domingo, C, Mares, V, Ploc, O, Trinkl, S, Harrison, R, Toltz, A, Nevitt, Z, Bloch, C, Taddei, P, Saini, J, Regmi, R, Yuntao, S, Jinxing, Z, Yap, J.S.L, Hentz, M, Silverman, J, Jolly, S, Boogert, S, Nevay, L, Kacperek, A, Schnuerer, R, Resta-Lopez, J, Zeng, X, Zheng, J, Li, M, Han, M, Song, Y, Holm, A, Korreman, S, Petersen, J.B.B, Bäumer, C, Fuenstes, C, Janson, M, Matic, A, Wulff, J, Psoroulas, S, Lomax, T, Arjomandy, B, Athar, B, Tesfamicael, B, Bejarano Buele, A, Deemer, J, Kozlyuk, V, VanSickle, K, Bolt, R, van Goethem, M.J, Langendijk, J, van t Veld, A, Chen, K.L, Wlodarczyk, B, Wu, H, Chen, Z, Shen, L, Fachouri, N, Placidi, L, Böhlen, T, Ieko, Y, Iwai, T, Nemoto, K, Suzuki, K, Kanai, T, Miyasaka, Y, Harada, M, Yamashita, H, Kubota, I, Kayama, T, Jensen, M.F, Bræmer-Jensen, P, Randers, P, Søndergaard, C.S, Nørrevang, O, Taasti, V.T, Kong, H, Yin, C, Gu, M, Liu, M, Shu, H, Chongxian, Y, Haiyang, Z, Juan, Z, Ming, L, Manzhou, Z., Liying, Z, Kecheng, C, Xiaolei, D, Castro, J, Freire, J, Cremades, M, Moral, L, Rico, P, Ares, C, Miralbell, R, Shi, J, Xia, J, Wang, B, Li, Q, Liu, X, Sung, C.C, Chen, W.P, Liao, T.Y, Takashina, M, Hamatani, N, Tsubouchi, T, Yagi, M, Mizoe, J, Titt, U, Mirkovic, D, Yepes, P, Wang, Q, Grosshans, D, Wieser, H.P, Mohan, R, Vadrucci, M, Xiao, G, Cai, X, Li, G, Yuan, Y, Lu, R, Sun, G, Zhang, M, Deming, L, lianhua, O, Takada, K, Tanaka, S, Matsumoto, Y, Naito, F, Kurihara, T, Nakai, K, Matsumura, A, Sakae, T, Shamurailatpam, D, P, K, Mp, N, A, M, Kg, G, T, R, C, S, J, R, Rozes, A, Dutheil, P, Batalla, A, Vela, A, Rana, S, Bennouna, J, Gutierrez, A, He, P, Shen, G, Dai, Z, Ma, Y, Chen, W, Pandey, J, Chirvase, C, Osborne, M, Ilsley, E, Di Biase, I, Kato, T, Hirose, K, Arai, K, Motoyanagi, T, Harada, T, Takeuchi, A, Kato, R, Tanaka, H, Mitsumoto, T, Takai, Y, Bolsa-Ferruz, M, Palmans, H, Chen, Y.S, Wu, S.W, Huang, H.C, Wang, H.T, Yeh, C.Y, Chen, H.H, Cook, H, Lourenço, A, Dal Bello, R, Magalhaes Martins, P, Hermann, G, Kihm, T, Seimetz, M, Brons, S, Seco, J, De Saint-Hubert, M, Swakon, J, De Freitas Nascimento, L, Tessaro, V.B, Poignant, F, Gervais, B, Beuve, M, Galassi, M.E, Harms, J, Chang, C.W, Zhang, R, Lin, Y, Langen, K, Liu, T, Lin, L, Howard, M, Denbeigh, J, Remmes, N, Debrot, E, Herman, M, Huang, Y.Y, Tsai, S.H, Fang, F.M, Mizuno, H, Sagara, T, Yamazaki, Y, Kato, M, Oyama, S, Pembroke, C, Joslin-Tan, T, Maggs, R, O’Neil, K, Barrett-Lee, P, Staffurth, J, Resch, A, Heyes, P, Georg, D, Fuchs, H, Hideyuki, M, katsuhisa, N, Wataru, Y, Samnøy, A.T, Ytre-Hauge, K.S, Povoli, M, Kok, A, Summanwar, A, Linh, T, Malinen, E, Röhrich, D, Asp, J, Santos, A, Afshar, V.S, Zhang, W.Q, Bezak, E, a, M, k, G, p, K, mp, N, t, R, c, S, j, R, Smith, B, Hammer, C, Hyer, D, DeWerd, L, Culberson, W, Brooke, M, Straticiuc, M, Craciun, L, Matei, C.E, Radu, M, Xiao, M, Paschalis, S, Joshi, P, Price, T, Mehta, M, Graça, J, Biglin, E, Aitkenhead, A, Price, G, Williams, K, Chadwick, A, Schettino, G, Robinson, A, Kirkby, K, Catanzano, D, Cessac, R, Rutherford, R, Ahmed, A, Mohammadi, A, Tashima, H, Yamaya, T, Chavez Barajas, C, Taylor, A, Vossebeld, J, Barwick, I, CHEON, W, Jo, K, Ahn, S.W, Cho, J, Han, Y, Choi, H.H.F, Cheung, C.W, Cohilis, M, Lee, J.A, Sterpin, E, Souris, K, Mundy, D, Petasecca, M, Rosenfeld, A.B, Boso, A, Di Fulvio, A, Becchetti, F.D, Torres-Isea, R.O, Febbraro, M, Gagnon-Moisan, F, Feng, Y, Fontana, M, Etxebeste, A, Dauvergne, D, Letang, J.M, Testa, E, Sarrut, D, Maxim, V, Gajewski, J, Durante, M, Garbacz, M, Krah, N, Krzempek, K, Schiavi, A, Skrzypek, A, Tommasino, F, Ruciński, A, Gillin, M, Sahoo, N, Zhu, X.R, Van Delinder, K.W, Crawford, D, Khan, R, Gräfe, J, Kakiuchi, G, Shioyama, Y, Shimokomaki, R, Huang, Z, Wang, W, Sheng, Y, Lee, M.W, Jan, M.L, Hong, J.H, Okamoto, K, Sato, H, Kalantan, S, Boston, A, Kang, Y, Shen, J, Casey, W, Vern-Gross, T, Wong, W, McGee, L, Halyard, M, Keole, S, Kelleter, L, Radogna, R, Saakyan, R, Basharina-Freshville, A, Attree, D, Volz, L, Komenda, W, Krzempek, D, Mierzwińska, G, Barbara, M, Kopeć, R, Lan, J.H, Chang, F.X, Lin, C.H, Lee, T.F, Ahn, S, Cheon, W, Lee, M, Letellier, V, Osorio, J, Dreindl, R, Livingstone, J, Gallin-Martel, M.L, Létang, J.M, Marcatili, S, Morel, C, Maggi, P, Chen, H, Yang, H, Panthi, R, Mackin, D, Peterson, S, Beddar, S, Polf, J, Masuda, T, Nishio, T, Sano, A, Tomozawa, H, Nishio, A, Tsuneda, M, Okamoto, T, Karasawa, K, Miszczynska Giza, O, Sánchez-Parcerisa, D, Herraiz, J. L, Rojo-Santiago, J, Udias, J.M, Mitrović, U, Hager, M, List, I, Fischer, C, Cecowski, M, Gajšek, R, Mizutani, S, Hotta, K, Baba, H, Tanizaki, N, Yamaguchi, T, Moon, S.Y, Rah, J.E, Yoon, M, Shin, D, Nebah, P, Dugas, J, Syh, J, Maynard, M, Marsh, N, Rosen, L, Nichiporov, D, Watts, D.A, Chen, Y, Petterson, M, Lee, W.D, Penfold, S.N, Ruebel, N, Piersimoni, P, Mille, M, Mossahebi, S, Chen-Mayer, H, Allport, P, Green, S, Shaikh, S, Walker, D, Qamhiyeh, S, Levegruen, S, Kutscher, S, Kranke, H, Olbrich, G, Stuschke, M, Baran, J, Pawlik-Niedzwiecka, M, Moskal, P, Rutherford, H, Poenisch, F, Martin, C, Wu, R, Mayo, L.L, Shah, S.J, Frank, S.J, Gunn, G.B, Sakurai, Y, Takata, T, Kondo, N, Schlegel, N, Deng, Y, Sun, W, Wu, X, Yap, J, Zhang, H, Szumlak, T, Schuy, C, Simeonov, Y, Zink, K, Graeff, C, Weber, U, Allred, B, Robertson, D, Dewees, T, Gagneur, J, Stoker, J, Stützer, K, Valentini, C, Agolli, L, Hölscher, T, Thiele, J, Dutz, A, Löck, S, Krause, M, Baumann, M, Richter, C, Takayanagi, T, Uesaka, T, Nakamura, Y, Unlu, M.B, Kuriyama, Y, Uesugi, T, Ishi, Y, Umegaki, K, Matsuura, T, Watts, D. A, Huisman, B, Valladolid Onecha, V, Fraile, L.M, Sanchez Parcerisa, D, España, S, Ze, W, Chen, H.Y, Chuang, K.S, Wilson, M, Lui, J, Noble, D, Holloway, S, Yap, J.H.H, Chew, M.M.L, Pang, P.P, Lim, C.J.C, Gan, S.A, Tan, T.W.K, Shen, Z.M, Moyers, M, Qianxia, W, Chen, H.L, Li, J, Lin, J, Zhao, L, Myers, W, Ates, O, Faught, J, Yan, Y, Faught, A, Sobczak, D, Hua, C.H, Moskvin, V, Merchant, T, Henkner, K, Ecker, S, Chaudhri, N, Ellerbrock, M, Jäkel, O, Hernandez Morales, D, Augustine, K, Johnson, J, Younkin, J, Fiorina, E, Mattei, I, Morrocchi, M, Sarti, A, Traini, G, Valle, S.M, Bert, C, Karger, C.P, Kamada, T, Scholz, M, DeLuca, P.M, De Simoni, M, Dong, Y, Embriaco, A, Fischetti, M, Mancini-Terracciano, C, Mirabelli, R, Muraro, S, Lens, E, de Blécourt, A, Schaart, D, Vos, F, van Dongen, K, Berthold, J, Khamfongkhruea, C, Petzoldt, J, Wohlfahrt, P, Pausch, G, Janssens, G, Smeets, J, Shamblin, J, Blakey, M, Moore, R, Matteo, J, Schreuder, N, Derenchuk, V, Shin, J, Jee, K.W, Clasie, B.M, Depauw, N, Batin, E, Madden, T.M, Schuemann, J, Paganetti, H, Kooy, H.M, Daniel, M, Abbassi, L, Arsène-Henry, A, Amessis, M, Maes, S, O’Ryan-Blair, A, Laval, G, Ermoian, R, Taddei, P. J, Andersson, K, Norrlid, O, Lindbäck, E, Vallhagen Dahlgren, C, Witt Nyström, P, Argota Perez, R, Sharma, M.B, Elstrøm, U.V, Bizzocchi, N, Albertini, F, Branco, D, Kry, S, Rong, J, Frank, S, Followill, D, Busch, K, Muren, L.P, Thörnqvist, S, Andersen, A.G, Pedersen, J, Dong, L, Cao, W, Bai, X, Van Lobenstein, N, Traneus, E, Anson, C, Comi, S, Marvaso, G, Russo, S, Giandini, T, Avuzzi, B, Ciardo, D, Cattani, F, Jereczek-Fossa, B, Cotterill, J, Esposito, M, Winter, A, Allinson, N, Liu, G, Yan, D, Jawad, S, Dilworth, J, Chen, P, Ackermann, B, Florijn, M, Sharfo, A.W.M, Wiggenraad, R.G.J, van Santvoort, J.P.C, Petoukhova, A.L, Hoogeman, M.S, Mast, M.E, Dirkx, M.L.P, Fujitaka, S, Fujii, Y, Nihongi, H, Nakayama, S, Ho, M.W, Artz, M, Tong, K.T.A, Hytonen, R, Koponen, T, Niemela, P, Iancu, G, Lautenschlaeger, S, Eberle, F, Horst, F, Ringbaek, T, Engenhart-Cabillic, R, Kim, M.J, Hong, C.S, Kim, Y.B, Park, S.H, Kim, J.S, Reiterer, J, Steffal, C, Gora, J, Kann, T, Schratter-Sehn, A.U, Li, H, Chen, M, wu, R, Li, Y, zhang, X, Gautam, A, poenisch, F, sahoo, N, Zhu, R, Lin, M, Chang, J.T.C, Maeda, Y, Sato, Y, Shibata, S, Bou, S, Yamamoto, K, Sasaki, M, Fuwa, N, Takamatsu, S, Kume, K, Lim, F, Faller, F, Stiller, W, Ming, X, Hui, H, Mukawa, T, Takashi, Y, Stephenson, L, Pang, E.P.P, Paz, A.E, Yoshida, Y, Righetto, R, Vecchi, C, Alparone, A, De Spirito, M, Radhakrishnan, S, Chandrashekaran, A, Nandigam, J, Sarma, Y, Rechner, L, Munck af Rosenschöld, P, Bäck, A, Johansen, T.S, Schut, D.A, Aznar, M.C, Nyman, J, Ren, X, Rosas, S, Vanderstraeten, R, Jyske, T, Jari, L, Yuenan, W, Henthorn, N, Warmenhoven, J, Merchant, M, Kirkby, N, Ranald, M, Stefanowicz, S, Zschaeck, S, Troost, E.G.C, Stubington, E, Ehrgott, M, Nohadani, O, Shentall, G, Sun, T, yin, Y, Lin, X, Yoshimura, T, Matsuo, Y, Yamazaki, R, Takao, S, Miyamoto, N, Toussaint, L, Indelicato, D.J, Lassen-Ramshad, Y, Kirby, K, Mikkelsen, R, Di Pinto, M, Høyer, M, Stokkevåg, C.H, Van Herk, M, Shortall, J, Green, A, Vasquez Osorio, E, Mackay, R, Navratil, M, Andrlik, M, Chiang, Y.Y, Yeh, Y.H, Yeh, Y.J, Chang, T.C, Eaton, B, Yang, X, Esiashvili, N, Gu, W, Ruan, D, O’Connor, D, Zou, W, Tsai, M.Y, Jia, X, Sheng, K, Hyde, C, Chen, P.Y, Deraniyagala, R, Petoukhova, A, Klaassen, L, Habraken, S, Jacobs, J, Sattler, M, Verhoeven, K, Klaver, Y, Widesott, L, Fracchiolla, F, Algranati, C, Scifoni, E, Scartoni, D, Farace, P, Kröniger, K, Bauer, J, Nilsson, R, Chen, X, Liu, R, Sun, B, Mutic, S, Zhang, T, Zhao, T, Kajdrowicz, T, Wochnik, A, Swakoń, J, Małecki, K, Michalec, B, Moffitt, G, Wootton, L, Hardemark, B, Sandison, G, Emery, R, Stewart, R, Reidel, C.A, Finck, C, Deisher, A, Mahajan, A, Michael, H, Ahn, S.H, Kwang Hyeon, K, Chankyu, K, Youngmoon, G, Shinhaeng, C, Se Byeong, L, Young Kyung, L, Haksoo, K, Dongho, S, Jong Hwi, J, Ali, Y, Monini, C, Maigne, L, Alshaikhi, J, D’Souza, D, Amos, R. A, Baumann, K.S, Gomà, C, Flatten, V, Lautenschläger, S, Abdel-Rehim, A, Wan Chan Tseung, H.S, Ma, J, Kamal Syed, H, Boscolo, D, Krämer, M, Fuss, M, Braunroth, T, Rabus, H, Baek, W.Y, Brown, H, Alshammari, H, Brownstein, J, Giantsoudi, D, Wang, C.C, Grassberger, C, Chen, C, Chan, M.F, Mah, D, Hojo, Y, Xu, C, Elia, A, Fung, A, Nguyen, B.N, Oyervides, M, Koska, B, Kamal Sayed, H, Kim, C, Kim, Y.J, Lee, S.B, Goh, Y, Cho, S, Jeong, J.H, Kim, H, Lim, Y.K, Koh, W.Y.C, Lew, W.S, Lee, C.L.J, Kollitz, E, Han, H, Kim, C.H, Kroll, C, Riboldi, M, Newhauser, W, Dedes, G, Fuglsang Jensen, M, Nyström, U.H, Skyt, P.S, Hoffmann, L, Sloth Møller, D, Dokic, I, Kuo, S.H, Tai, P.L, Cheng, S.W, Chong, N.S, Yeom, Y.S, Kuzmin, G, Griffin, K, Langner, U, Jung, J.W, Lee, C, Lee, C.C, Hsu, W, Chao, T.C, Liamsuwan, T, Pischom, N, Tangboonduangjit, P, Suchada, T, Zheng, D, Rutenberg, M, Dhabaan, A, Harrabi, S, MARAFINI, M, Gioscio, E, Yunsheng, D, Alphonse, G, Rodriguez Lafrasse, C, Testa, É, Morris, B, Asavaphatiboon, S, DeBlois, D, Yam, M, Sękowski, P, Skwira-Chalot, I, Matulewicz, T, Flynn, R, Verbeek, N, Smyczek, S, Brualla, L, Lei, Y, Ghavidel, B, Curran, W, Beitler, J, Yu, H.W, Jeng, S.C, Tsai, Y.C, Chiou, J.F, Yusa, K, Dai, T, Yuan, P, Shafai-Erfani, G, Shu, H.K, Pepin, M, Tryggestad, E.J, Abdel Rehim, A, Johnson, J.E, Herman, M.G, Lee, S.C, Sheu, R.J, Ödén, J, Ramos-Mendez, J, Perl, J, Faddegon, B, Alaka, B.G, Bentefour, E.H, Samuel, D, Biradar, B, Frusti, P, Den Otter, L.A, Kurz, C, Stanislawski, M, Landry, G, Meijers, A, Knopf, A.C, Dickmann, J, Wesp, P, Rit, S, Johnson, R.P, Bashkirov, V, Schulte, R.W, Hoyle, B, Johnson, R, Schulte, R, Weller, J, Cotterill, J.V, Waltham, C, Allport, P.P, Taylor, M, Rogers, J, Evans, P.M, Allinson, N.M, Henry, T, Ardenfors, O, Gudowska, I, Poludniowski, G, Dasu, A, Lai, Y, Yuncheng, Z, Yiping, S, Mingwu, J, Xun, J, Yujie, C, Meric, I, Mattingly, J, Moustafa, A, Skjerdal, K, Moteabbed, M, Harisinghani, M, Efstathiou, J.A, Lu, H.M, Kabuki, S, Mizowaki, T, Ofierzynski, R, Paysan, P, Strzelecki, A, Lucca, R, Patch, S, Mustapha, B, Santiago-Gonzalez, D, Pettersen, H.E.S, Sølie, J, Levegrün, S, Pöttgen, C, Meyer, E, Collins-Fekete, C.A, Bashkirov, V.A, Wang, Y.M, Sung, K.C, Wang, C.J, Wu, H.Y, Winter, M, Bauer, U, Hansmann, T, Naumann, J, Peters, A, Pilz, K, Troost, E, Yan, S, Greenhalgh, J, Li, S, Bortfeld, T, Flanz, J, Ytre-Hauge, K, Zhang, L, Sharp, G.C, Cascio, E.W, Flanz, J.B, Tang, J, Zhu, J, Zhang, J, Uh, J, Sarosiek, C, Ricci, J, Coutrakon, G, Ozoemelam, I, van der Graaf, E.R, Maciej, K, Zhang, N, Brandenburg, S, Dendooven, P, Niepel, K, Yohannes, I, Dietrich, O, Ertl-Wagner, B, Pappas, E, Sølie, J.R, Odland, O.H, Ghesquiere-Dierickx, L.M.H, Felix Bautista, R, Gehrke, T, Jakubek, J, Turecek, D, Martisikova, M, Malekzadeh, E, Rajabi, H, Kalantari Mahmoudabadi, F, Meschini, G, d’Arenzo, D, Comini, D, Huynh, M.T, Paganelli, C, Fontana, G, Mancin, A, Preda, L, Su, Z, Henderson, R, Nichols, C, Bryant, C, Mendenhall, W, Boyer, B, Geerebaert, Y, Gevin, O, Koumeir, C, Magniette, F, Manigot, P, Poirier, F, Servagent, N, Thiebaux, C, Verderi, M, Chen, Y.R, Anderle, K, Jeraj, R, Chuter, R, Allan, I, Patel, I, MacKay, R, Harrison, K, Hoole, A, Thomas, S, Jena, R, Liao, Z, Zhu, R.X, Freeman, M, Espy, M, Aulwes, E, Magnelind, P, Merrill, F, Neukirch, L, Sidebottom, R, Tang, Z, Tupa, D, Wilde, C, Shusharina, N, Fullerton, B, Adams, J, Sharp, G, Chan, A, Dolde, K, Naumann, P, Dávid, C, Kachelrieß, M, Saito, N, Pfaffenberger, A, Wolf, M, Lis, M, Moreau, J, Buttion, M, Molitoris, J.K, Simone-, C.B, Regele, H, Bula, C, Danuser, S, Kang, M, Lin, H, Ribeiro, C. O, Dumont, D, Terpstra, J, Knopf, A, Wagenaar, D, Kierkels, R, van der Schaaf, A, Scandurra, D, Sijtsema, M, Korevaar, E, van den Hoek, A, O’Neil, M, Chung, H, Sala, I, Ramirez, H, Guerrero, T, Mondlane, G, Butkus, M.B, Stewart, R.D, Carlson, D.J, Ingram, S, Ytre-Hauge, K. Smeland, Rørvik, E, Perales, A, Carabe, A, Baratto-Roldan, A, Kimstrand, P, Cortes-Giraldo, M, Bertolet, A, Barato-Roldan, A, Baiocco, G, Barbieri, S, Mei, Z, Fan, K, Tang, K, Wang, J, Zhu, H, Sung, W, McNamara, A, Tran, L.T, Qi, Y, Xu, X, Pei, X, Chiang, Y, Chien-Hau, C, Chung-Chi, L, Chuan-Jong, T, Tsi-Chian, C, Wang, L, Cao, J, Wang, X, Lin, E, Minami, K, Kondo, R, Khoei, S, Shirvalilou, S, Khoee, S, Jamali Raoufi, N, Karimi, M.R, Shakeri-Zadeh, A, Patera, V, Rinaldi, I, Sas-Korczynska, B, Deng, W, Karagounis, I, Huynh, K, Maity, A, Abel, E, Santa Cruz, G, Monti Hughes, A, Herrera, M, Trivillin, V, Portu, A, Garabalino, M, Schwint, A, Gonzalez, S, Saint Martin, G, Santa Cruz, I, Tamari, Y, Watanabe, T, Masunaga, S.I, Wittig, A, Nigg, D, Stecher-Rasmussen, F, Moss, R, Igawa, K, Akita, K, Akabori, K, Hattori, K.J, Arima, H, Motoyama, K, Higashi, T, Trivillin, V.A, Pozzi, E.C.C, Thorp1, S.I, Curotto1, P, Garabalino1, M.A, Itoiz, M.E, Santa Cruz, I.S, Ramos, P.S, Palmieri, M.A, Schwint, A.E, Gadan, M.A, Thorp, S.I, Curotto, P, Portu, A.M, Thorp, S, Trivillin, V. A, Schwint, A. E, Fukuo, Y, Kanemitsu, T, Fukumura, M, Kosaka, T, Hiramatsu, R, Kuroiwa, T, Miyatake, S, Kawabata, S, Kirihata, M, Goldfinger, J.A, Garabalino, M.A, Pozzi, E.C, Ramos, P, De Leo, L.N, Yu, Q, Engelbrecht, M, Sioen, S, Miles, X, Nair, S, Ndimba, R, Baeyens, A, Vandevoorde, C, Buizza, G, Meng, J, Takai, N, Ogami, M, Nakamura, S, Ohba, Y, Liu, R.F, Zhang, Q.N, Wang, X.H, Luo, H.T, Kong, Y.R, Jansen, J, Tirinato, L, Marafioti, M.G, Hanley, R, Yao, X.Q, Pagliari, F, Huang, C.Y, Wong, W.K.R, Ho, Y.W, Nam, P.H, Koryakin, S.N, Troshina, M.V, Koryakina, E.V, Potetnya, V.I, Baykuzina, R.M, Lychagin, A.A, Ulyanenko, S.E, Molinelli, S, Giuseppe, M, Tran, L, Bolst, D, James, B, Steinsberger, T, Alliger, C, Dahle, T.J, Rusten, E, Wright, P, Forsback, S, Silvoniemi, A, Minn, H, Andersson, S, Buti, G, Barragán Montero, A.M, Vasquez-Osario, E, Sabouri, P, Nkenge, K, Yi, B, Burigo, L, Greilich, S, Thomas, R, Clark, C, Lourenco, A, Oancea, C, Granja, C, Kodaira, S, Coplan, M, Graybill, J, Lutz, L, Shahi, C, Su, J.J, Thompson, A, Romano, F, Shipley, D, Hong, T.S, Labarbe, R, Wolfgang, J.A, Meyer, S, Bortfeldt, J, Lämmer, P, Schnürle, K, Peters, N, Möhler, C, Hofmann, C, Koschik, A, Bryce-Atkinson, A, Van Nugteren, J, De Rijk, G, Kirby, G, Dutoit, B, Vignati, A, Ahmadi Ganjeh, Z, Fausti, F, Giordanengo, S, Hammad Ali, O, Sacchi, R, Shakarami, Z, Cirio, R, Inoue, J, Tachibana, M, Shimizu, Y, Ochi, T, Amano, D, Miyashita, T, Cooley, J, Nyamane, S, Zwart, T, Wagner, M, Lu, M, Rosenthal, S, Hashimoto, T, Katoh, N, Tamura, H, Emert, F, Missimer, J, Eichenberger, P, Gmuer, C, Spengler, C, Kamp, F, Hofmaier, J, Reiner, M, Belka, C, Van Ooteghem, G, Dasnoy-Sumell, D, Geets, X, Chen, C.C, Galbreath, G, Shmulenson, R, Pinheiro de Almeida, I, van Elmpt, W, Vilches Freixas, G, Unipan, M, Verhaegen, F, Bosmans, G, Garcia, G, Cevallos Robalino, L, Guzman-Garcia, K, Vega-Carrillo, H.R, Gomez-Ros, J.M, Gallego, E, Hintenlang, K, Martin, M, Gupta, N, Meissner, J, Smathers, J, Ainsley, C, Yin, L, Jagt, T, Breedveld, S, van Haveren, R, Nout, R, Astreinidou, E, Staring, M, Heijmen, B, Hoogeman, M, Stokes, W, Matter, M, Nenoff, L, Toramatsu, C, Wakizaka, H, Nitta, M, Nishikido, F, Hirano, Y, Yoshida, E, Miller, J, Maris, A, Kalle, R, Franco, G, Kierkels, R.G.J, van den Hoek, J.G.M, Bijl, H.P, Dieters, M, Steenbakkers, R.J.H.M, Dejongh, F, DeJongh, E, Rykalin, V, Karonis, N, Ordonez, C, Duffin, K, Winans, J, Neph, R, Sanchez-Parcerisa, D, Lopez-Aguirre, M, Dolcet Llerena, A, Udias, J, Oxley, D, Besson, R, Meier, G, Nanz, A, Schorta, M, Fleury, E, Trnková, P, Erdal, E, Hassan, K, Beenakker, J.W, Pignol, J.P, Matysiak, W, Tian, L, Zepter, S, Winterhalter, C, Shim, S, Gouldstone, C, Trnkova, P, Vatnitsky, S, Liu, K, Li, E, Zhuangming, S, Lowenstein, J, De Wilde, O, Bossier, V, Lerot, X, Pouppez, A, Xx, X, Verburg, J, Hueso-Gonzalez, F, Ruggieri, T, Amato, C, Ghesquiere-Dierickx, L, Felix-Bautista, R, Deville, C, Barsky, A, Vapiwala, N, Mohamad, O, Tabuchi, T, Nitta, Y, Nomoto, A, Kasuya, G, Choy, H, Miyashiro, I, Bush, D, Chuong, M, Kozarek, J, Rubens, M, Larson, G, Vargas, C, Hung, S.P, Hsieh, C.E, Huang, B.S, Tsang, N.M, Smith, N, Viehman, J, Harmsen, W, Elswick, S, Boughey, J, Harless, C, Jimenez, R, Hickey, S, DePauw, N, Ho, A, Taghian, A, MacDonald, S, Meek, A, Hedrick, S, Baliga, S, Gallotto, S, Lewy, J, Patteson, B, Speroni, S, Omsberg, A, Tarbell, N, Musolino, P, Yock, T, Indelicato, D, Rotondo, R, Mailhot, R, Uezono, H, Bradfield, S, Agarwal, V, Gillies, C, Gosling, A, Casares-Magaz, O, Eskildsen, S.F, Lassen, Y, Hasle, H, Tofting-Olesen, K, Alapetite, C, Puget, S, Nauraye, C, Beccaria, K, Bolle, S, Doz, F, Sainte-Rose, C, Bouffet, E, Zerah, M, Wu, J, Qiu, X, Hua, W, Mao, Y, Frakulli, R, Kramer, P.H, Glas, M, Blase, C, Tippelt, S, Konrath, L, Gruber, N, Schallerbauer-Peter, A, Mock, U, Niyazi, M, Niemierko, A, Schapira, E, Kim, V, Oh, K.S, Hwang, W.L, Busse, P.M, Loeffler, J.S, Shih, H.A, Appel, H, Tseng, Y.D, Tsai, H, Sinesi, C, Rossi, C, Badiyan, S, Kotecha, R, Pike, L, Horick, N, Yeap, B, Franck, K, Wang, I, Loeffler, J, McKenna, M, Shih, H, Kountouri, M, Kole, A.J, Murray, F.R, Kliebsch, U, Combescure, C, iannalfi, A, Riva, G, Dougherty, J, Kruse, J, Iott, M, Brown, P, Olivier, K, Brodin, P, Kabarriti, R, Schechter, C, Kalnicki, S, Garg, M, Tomé, W, Lu, J.J, Chen, P.J, Dhanireddy, B, Severo, C, Lee, C.H, Lin, C.R, Rosier, L, Mathis, T, DeLaney, T, Lin, S, O’Meara, E, Powell, T, Hong, T, Hall, D, Liu, A, Ntentas, G, Dedeckova, K, Darby, S, Cutter, D, Zapletalova, S, Chen, Y.L, Miao, R, Lee, H, Hsiao-Ming, L, Choy, E, Cote, G, Eulitz, J, Lutz, B, Enghardt, W, Lühr, A, Mcmahon, S, Prise, K, Sung Hyun, L, Tansho, R, Mizushima, K, Warmenhoven, J.W, Hufnagl, A, Friedrich, T, Deycmar, S, Gruber, S, Dörr, W, Pruschy, M, Waissi, W, Burckel, H, Nicol, A, Noel, G, Yousef, I, Koizumi, M, Santa Cruz, G.A, González, S.J, Longhino, J, Provenzano, L, Oña, P, Rao, M, Cantarelli, M.D.L.Á, Leiras, A, Olivera, M.S, Alessandrini, P, Brollo, F, Boggio, E, Costa, H, Ventimiglia, R, Binia, S, Nievas, S.I, Langle, Y, Eijan, A.M, Colombo, L.L, Kawai, K, Nakamura, H, Natsuko, K, Masaki, H, Nakada, M, Furuse, M, Miyatake, S.I, Koivunoro, H, Kankaanranta, L, González, S, Joensuu, H, Sokol, O, Hild, S, Wiedemann, J, Köthe, A, Perry, D, Batie, M, Mascia, A, Sertorio, M, Luhr, A, Suckert, T, Müller, J, Beyreuther, E, Gotz, M, Haase, R, Schürer, M, Tillner, F, von Neubeck, C, Davis, A, Sishc, B, Saha, J, Ding, L, Story, M, Wagner, S, Kim, S.Y, Geary, S, Woodruff, T, Xu, T, Meng, Q, Gilchrist, S, Perentesis, J.P, Zheng, Y, Wells, S.I, Kong, Y, Liu, Y, Geng, Y, Knoll, M, Schwager, C, Schlegel, J, Schnölzer, M, Ding, L.H, Aroumougame, A, Chen, B, Saha, D, Pompos, A, Carter, R, Nickson, C, Thomson, J, Hill, M, Rodrigues, D, Snider, J, Sharma, A, Zakhary, M, Kara, L, Vujaskovic, Z, Dykstra, M, Best, T, Keane, F, Khandekar, M, Fintelmann, F, Willers, H, Singh, P, Eley, J, Malyapa, R, Mahmood, J, Hårdemark, B, Sandison, G.A, Wootton, L.S, Miyoaka, R.S, Laramore, G.E, Yang, P, van der Weide, H, Maduro, J, Heesters, M, Gawryszuk, A, Davila-Fajardo, R, Langendijk, H, Eckhard, M, Maxwell, A, VanNamen, K, Cashin, M, Jacovic, A, Dunn, M, kim, T, Jung, J, Kim, J, Swerdloff, S, Saunders, A, Thomas, J, Kidani, T, Okada, A, Tomida, K, Pennington, H, Xiaoqiang, L, Weigang, H, An, Q, Di, Y, Craig, S, Inga, G, Peyman, K, Xuanfeng, D, Cunningham, C, de Kock, M, Slabbert, J, Panaino, C.M, Phoenix, B, Regan, P.H, Shearman, R, Collins, S.M, Taylor, M.J, Grayson, M, Kato, K, Choi, H, Jang, J.W, Shin, W.G, Min, C.H, McMahon, S, Padilla Cabal, F, Fragoso, J.A, Resch, A.F, Katsis, A, Girdhani, S, Marshall, A, Jackson, I, Bentzen, S, Parry, R, Gantz, S, Schellhammer, S, Hoffmann, A, Delorme, R, Dos Santos, M, Salmon, R, Öden, J, Bullivant, K, Rucksdashal, R, Ferret, E, Covington, F, Rice, S, Decesaris, C, Siddiqui, O, Kowalski, E, Samanta, S, and Rothwell, B
- Subjects
Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0642 ,Physics: Absolute and Relative DosimetryPTC58-0180 ,Biology: Biology and Clinical InterfacePTC58-0685 ,Physics: Commissioning New FacilitiesPTC58-0385 ,Physics: 4D Treatment and DeliveryPTC58-0546 ,Clinics: EyePTC58-0714 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0528 ,Physics: Quality Assurance and VerificationPTC58-0507 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0661 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0221 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0531 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0653 ,Biology: Drug and Immunotherapy CombinationsPTC58-0163 ,Clinics: Sarcoma - LymphomaPTC58-0055 ,Biology: Drug and Immunotherapy CombinationsPTC58-0166 ,Clinics: CNS / Skull BasePTC58-0198 ,Physics: Treatment PlanningPTC58-0421 ,Clinics: PediatricsPTC58-0560 ,General: New HorizonsPTC58-0709 ,Physics: Treatment PlanningPTC58-0664 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0286 ,Physics: Treatment PlanningPTC58-0666 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0346 ,Physics: Treatment PlanningPTC58-0547 ,Physics: Treatment PlanningPTC58-0308 ,Physics: Treatment PlanningPTC58-0549 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0111 ,Physics: Absolute and Relative DosimetryPTC58-0050 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0587 ,Biology: Biology and Clinical InterfacePTC58-0454 ,Physics: Absolute and Relative DosimetryPTC58-0052 ,Physics: Commissioning New FacilitiesPTC58-0395 ,Physics: 4D Treatment and DeliveryPTC58-0534 ,Physics: Dose Calculation and OptimisationPTC58-0072 ,Physics: 4D Treatment and DeliveryPTC58-0533 ,Physics: 4D Treatment and DeliveryPTC58-0538 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0113 ,Physics: Quality Assurance and VerificationPTC58-0633 ,Physics: Treatment PlanningPTC58-0431 ,Physics: Beam Delivery and Nozzle DesignPTC58-0230 ,Biology: Mathematical Modelling SimulationPTC58-0179 ,Clinics: Head and Neck / EyePTC58-0365 ,Physics: Treatment PlanningPTC58-0319 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0697 ,Biology: Biology and Clinical InterfacePTC58-0663 ,Physics: Commissioning New FacilitiesPTC58-0240 ,Physics: Adaptive TherapyPTC58-0177 ,Physics: Commissioning New FacilitiesPTC58-0363 ,Physics: Commissioning New FacilitiesPTC58-0487 ,Physics: 4D Treatment and DeliveryPTC58-0209 ,Physics: 4D Treatment and DeliveryPTC58-0206 ,Clinics: CNS / Skull BasePTC58-0294 ,Physics: Commissioning New FacilitiesPTC58-0127 ,Biology: Mathematical Modelling SimulationPTC58-0068 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0062 ,Physics: 4D Treatment and DeliveryPTC58-0692 ,Physics: Quality Assurance and VerificationPTC58-0723 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0494 ,Physics: Treatment PlanningPTC58-0643 ,Physics: Treatment PlanningPTC58-0521 ,Physics: Treatment PlanningPTC58-0402 ,Physics: Treatment PlanningPTC58-0405 ,Clinics: Head and Neck / EyePTC58-0273 ,Clinics: GIPTC58-0397 ,Physics: Treatment PlanningPTC58-0648 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0489 ,Physics: Quality Assurance and VerificationPTC58-0617 ,Physics: Quality Assurance and VerificationPTC58-0616 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0668 ,Clinics: CNS / Skull BasePTC58-0188 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0625 ,Physics: Treatment PlanningPTC58-0654 ,Physics: Treatment PlanningPTC58-0655 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0133 ,Clinics: PediatricsPTC58-0313 ,Physics: Treatment PlanningPTC58-0659 ,Poster AbstractsClinics: CNSPTC58-0290 ,Physics: Commissioning New FacilitiesPTC58-0064 ,Physics: Adaptive TherapyPTC58-0396 ,Physics: Dose Calculation and OptimisationPTC58-0281 ,Physics: Quality Assurance and VerificationPTC58-0427 ,Physics: Quality Assurance and VerificationPTC58-0669 ,General: New Horizons SessionPTC58-0191 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0217 ,Physics: Quality Assurance and VerificationPTC58-0303 ,Physics: Quality Assurance and VerificationPTC58-0665 ,Clinics: Sarcoma - LymphomaPTC58-0495 ,Physics: Dose Calculation and OptimisationPTC58-0398 ,Physics: Quality Assurance and VerificationPTC58-0667 ,Physics: Quality Assurance and VerificationPTC58-0425 ,Physics: Quality Assurance and VerificationPTC58-0541 ,Physics: Treatment PlanningPTC58-0584 ,Physics: Quality Assurance and VerificationPTC58-0540 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0163 ,Physics: Treatment PlanningPTC58-0224 ,Physics: Treatment PlanningPTC58-0229 ,Clinics: PediatricsPTC58-0249 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0555 ,Clinics: PediatricPTC58-0463 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0556 ,Physics: Absolute and Relative DosimetryPTC58-0498 ,Physics: Commissioning New FacilitiesPTC58-0078 ,Physics: Dose Calculation and OptimisationPTC58-0270 ,Physics: Dose Calculation and OptimisationPTC58-0032 ,Physics: Dose Calculation and OptimisationPTC58-0274 ,Physics: 4D Treatment and DeliveryPTC58-0614 ,Physics: Dose Calculation and OptimisationPTC58-0026 ,Clinics: Head and Neck / EyePTC58-0280 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0091 ,Physics: Treatment PlanningPTC58-0593 ,Biology: Drug and Immunotherapy CombinationsPTC58-0012 ,Physics: Dose Calculation and OptimisationPTC58-0025 ,Physics: Dose Calculation and OptimisationPTC58-0146 ,Clinics: Sarcoma - LymphomaPTC58-0261 ,Physics: Treatment PlanningPTC58-0110 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0733 ,Physics: Quality Assurance and VerificationPTC58-0554 ,Physics: Treatment PlanningPTC58-0597 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0330 ,Physics: Treatment PlanningPTC58-0115 ,Physics: Treatment PlanningPTC58-0598 ,Physics: Absolute and Relative DosimetryPTC58-0040 ,Physics: Absolute and Relative DosimetryPTC58-0282 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0399 ,Physics: Absolute and Relative DosimetryPTC58-0283 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0569 ,Clinics: GUPTC58-0647 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0506 ,Physics: Commissioning New FacilitiesPTC58-0047 ,Physics: Dose Calculation and OptimisationPTC58-0067 ,Clinics: GUPTC58-0409 ,Physics: Dose Calculation and OptimisationPTC58-0065 ,Biology: BNCT Poster Discussion SessionsPTC58-0586 ,Physics: Absolute and Relative Dosimetry PTC58-0393 ,Physics: Image GuidancePTC58-0712 ,Physics: Quality Assurance and VerificationPTC58-0645 ,Physics: Treatment PlanningPTC58-0683 ,Biology: BNCT Poster Discussion SessionsPTC58-0107 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0266 ,Physics: Monitoring and Modelling MotionPTC58-0530 ,Biology: BNCT Poster Discussion SessionsPTC58-0341 ,Physics: Commissioning New FacilitiesPTC58-0172 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0456 ,Physics: Dose Calculation and OptimisationPTC58-0170 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0458 ,Physics: Absolute and Relative DosimetryPTC58-0034 ,Physics: Quality Assurance and VerificationPTC58-0417 ,Physics: Quality Assurance and VerificationPTC58-0413 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0492 ,Physics: Dose Calculation and OptimisationPTC58-0168 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0724 ,Physics: Treatment PlanningPTC58-0694 ,Physics: Adaptive TherapyPTC58-0005 ,Physics: Treatment PlanningPTC58-0696 ,Physics: Treatment PlanningPTC58-0453 ,Physics: Adaptive TherapyPTC58-0366 ,Clinics: BreastPTC58-0197 ,Physics: Beam Delivery and Nozzle DesignPTC58-0652 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0017 ,Physics: Treatment PlanningPTC58-0338 ,Clinics: Head and Neck / EyePTC58-0539 ,General: New Horizons SessionPTC58-0390 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0651 ,General: New HorizonsPTC58-0660 ,Physics: Dose Calculation and OptimisationPTC58-0360 ,Physics: Image GuidancePTC58-0297 ,Physics: 4D Treatment and DeliveryPTC58-0147 ,Scientific: RTTPTC58-0388 ,Physics: Dose Calculation and OptimisationPTC58-0484 ,General: New HorizonsPTC58-0301 ,Physics: Dose Calculation and OptimisationPTC58-0485 ,General: New HorizonsPTC58-0304 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0532 ,Clinics: GIPTC58-0575 ,General: New HorizonsPTC58-0306 ,Physics: Quality Assurance and VerificationPTC58-0589 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0344 ,Physics: Quality Assurance and VerificationPTC58-0225 ,Physics: Treatment PlanningPTC58-0381 ,Physics: Quality Assurance and VerificationPTC58-0467 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0585 ,Physics: Commissioning New FacilitiesPTC58-0416 ,Physics: Quality Assurance and VerificationPTC58-0228 ,Physics: Quality Assurance and VerificationPTC58-0348 ,Physics: Dose Calculation and OptimisationPTC58-0234 ,Physics: Quality Assurance and VerificationPTC58-0101 ,Physics: Treatment PlanningPTC58-0386 ,Physics: Dose Calculation and OptimisationPTC58-0118 ,Physics: Treatment PlanningPTC58-0265 ,Physics: Dose Calculation and OptimisationPTC58-0119 ,Clinics: GIPTC58-0218 ,Physics: Treatment PlanningPTC58-0267 ,Physics: Treatment PlanningPTC58-0387 ,Clinics: BreastPTC58-0142 ,Physics: Treatment PlanningPTC58-0269 ,Physics: Beam Delivery and Nozzle DesignPTC58-0620 ,Clinics: PediatricsPTC58-0048 ,Physics: Quality Assurance and VerificationPTC58-0220 ,Physics: Quality Assurance and VerificationPTC58-0461 ,Physics: Treatment PlanningPTC58-0029 ,Physics: Absolute and Relative DosimetryPTC58-0571 ,Physics: Image GuidancePTC58-0046 ,Clinics: GUPTC58-0557 ,Physics: Absolute and Relative DosimetryPTC58-0211 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0131 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0373 ,General: New HorizonsPTC58-0411 ,Physics: Dose Calculation and OptimisationPTC58-0595 ,Clinics: CNS / Skull BasePTC58-0361 ,General: New HorizonsPTC58-0414 ,General: New HorizonsPTC58-0537 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0628 ,Physics: Treatment PlanningPTC58-0271 ,Physics: Commissioning New FacilitiesPTC58-0307 ,Physics: Quality Assurance and VerificationPTC58-0359 ,Physics: Quality Assurance and VerificationPTC58-0354 ,General: New HorizonsPTC58-0419 ,Physics: Treatment PlanningPTC58-0035 ,Biology: BNCTPTC58-0474 ,Clinics: GIPTC58-0460 ,Biology: BNCTPTC58-0596 ,Clinics: GIPTC58-0222 ,Physics: Image GuidancePTC58-0193 ,Clinics: PediatricPTC58-0312 ,Clinics: GUPTC58-0441 ,Clinics: LungPTC58-0701 ,Clinics: EyePTC58-0536 ,Clinics: GUPTC58-0205 ,Physics: Dose Calculation and OptimisationPTC58-0140 ,Clinics: GUPTC58-0208 ,Physics: Dose Calculation and OptimisationPTC58-0020 ,Physics: Image GuidancePTC58-0195 ,Poster AbstractsClinics: CNSPTC58-0717 ,Physics: Quality Assurance and VerificationPTC58-0325 ,Physics: Dose Calculation and OptimisationPTC58-0015 ,Physics: Commissioning New FacilitiesPTC58-0634 ,General: New HorizonsPTC58-0646 ,Physics: Quality Assurance and VerificationPTC58-0566 ,Physics: Dose Calculation and OptimisationPTC58-0134 ,Physics: Dose Calculation and OptimisationPTC58-0376 ,Biology: Mathematical Modelling SimulationPTC58-0462 ,Biology: BNCTPTC58-0567 ,General: New HorizonsPTC58-0527 ,Physics: Treatment PlanningPTC58-0482 ,Clinics: GI, GU, BreastPTC58-0693 ,Physics: Commissioning New FacilitiesPTC58-0518 ,Physics: Quality Assurance and VerificationPTC58-0686 ,Physics: Quality Assurance and VerificationPTC58-0202 ,Physics: Quality Assurance and VerificationPTC58-0322 ,Physics: Quality Assurance and VerificationPTC58-0564 ,Physics: Quality Assurance and VerificationPTC58-0680 ,Physics: Treatment PlanningPTC58-0247 ,Physics: Quality Assurance and VerificationPTC58-0682 ,Physics: Quality Assurance and VerificationPTC58-0440 ,Biology: Translational and BiomarkersPTC58-0514 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0178 ,Clinics: EyePTC58-0520 ,Physics: Absolute and Relative DosimetryPTC58-0231 ,Clinics: Head and Neck / EyePTC58-0424 ,Physics: Absolute and Relative DosimetryPTC58-0471 ,Physics: Absolute and Relative DosimetryPTC58-0356 ,Physics: Dose Calculation and OptimisationPTC58-0491 ,Physics: Dose Calculation and OptimisationPTC58-0250 ,Physics: Commissioning New FacilitiesPTC58-0650 ,Biology: Biology and Clinical InterfacePTC58-0719 ,Physics: Absolute and Relative DosimetryPTC58-0232 ,Physics: Absolute and Relative DosimetryPTC58-0353 ,General: New HorizonsPTC58-0511 ,Physics: Quality Assurance and VerificationPTC58-0219 ,Physics: Absolute and Relative DosimetryPTC58-0238 ,General: New HorizonsPTC58-0512 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0401 ,Clinics: PediatricPTC58-0688 ,Physics: Quality Assurance and VerificationPTC58-0457 ,Physics: Quality Assurance and VerificationPTC58-0214 ,Physics: Quality Assurance and VerificationPTC58-0459 ,General: New HorizonsPTC58-0516 ,Physics: Treatment PlanningPTC58-0372 ,Physics: Treatment PlanningPTC58-0011 ,Physics: Treatment PlanningPTC58-0254 ,Physics: Quality Assurance and VerificationPTC58-0332 ,Clinics: CNS / Skull BasePTC58-0468 ,Biology: Mathematical Modelling SimulationPTC58-0357 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0649 ,Physics: Dose Calculation and OptimisationPTC58-0006 ,Physics: Quality Assurance and VerificationPTC58-0212 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0565 ,Physics: Treatment PlanningPTC58-0018 ,Physics: Treatment PlanningPTC58-0019 ,Clinics: BreastPTC58-0576 ,Clinics: Head and Neck / EyePTC58-0335 ,Clinics: Head and Neck / EyePTC58-0577 ,General: New HorizonsPTC58-0621 ,Physics: Absolute and Relative DosimetryPTC58-0426 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0268 ,Physics: Absolute and Relative DosimetryPTC58-0423 ,Physics: Treatment PlanningPTC58-0184 ,Physics: Quality Assurance and VerificationPTC58-0149 ,Clinics: GIPTC58-0378 ,Clinics: GIPTC58-0257 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0662 ,General: New HorizonsPTC58-0627 ,Physics: Treatment PlanningPTC58-0186 ,Physics: Treatment PlanningPTC58-0185 ,Physics: Quality Assurance and VerificationPTC58-0144 ,Biology: BNCT Poster Discussion SessionsPTC58-0602 ,Physics: Treatment PlanningPTC58-0189 ,Physics: Dose Calculation and OptimisationPTC58-0315 ,Clinics: Head and neckPTC58-0300 ,General: New Horizons SessionPTC58-0347 ,Physics: Image GuidancePTC58-0082 ,Clinics: BreastPTC58-0443 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0629 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0007 ,Physics: Commissioning New FacilitiesPTC58-0472 ,Clinics: GI, GU, BreastPTC58-0515 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0606 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0450 ,Physics: Absolute and Relative DosimetryPTC58-0657 ,Physics: Dose Calculation and OptimisationPTC58-0551 ,Physics: Treatment PlanningPTC58-0192 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0675 ,Physics: Treatment PlanningPTC58-0194 ,Physics: Dose Calculation and OptimisationPTC58-0544 ,Physics: Treatment PlanningPTC58-0199 ,Physics: Quality Assurance and VerificationPTC58-0037 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0207 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0434 ,Physics: Quality Assurance and VerificationPTC58-0036 ,Physics: Quality Assurance and VerificationPTC58-0278 ,Physics: Quality Assurance and VerificationPTC58-0394 ,Physics: Quality Assurance and VerificationPTC58-0151 ,Physics: Quality Assurance and VerificationPTC58-0154 ,Physics: Dose Calculation and OptimisationPTC58-0428 ,Clinics: BreastPTC58-0116 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0435 ,Physics: Commissioning New FacilitiesPTC58-0681 ,Physics: Absolute and Relative DosimetryPTC58-0323 ,Physics: Dose Calculation and OptimisationPTC58-0583 ,Physics: Absolute and Relative DosimetryPTC58-0448 ,Clinics: CNS / Skull BasePTC58-0251 ,General: New HorizonsPTC58-0721 ,Physics: Absolute and Relative DosimetryPTC58-0203 ,Physics: Dose Calculation and OptimisationPTC58-0455 ,Physics: 4D Treatment and DeliveryPTC58-0130 ,Physics: Commissioning New FacilitiesPTC58-0679 ,Physics: Absolute and Relative DosimetryPTC58-0329 ,General: New HorizonsPTC58-0604 ,Physics: Absolute and Relative DosimetryPTC58-0449 ,Clinics: CNS / Skull BasePTC58-0132 ,General: New HorizonsPTC58-0607 ,Physics: Quality Assurance and VerificationPTC58-0122 ,Physics: Quality Assurance and VerificationPTC58-0243 ,Physics: Treatment PlanningPTC58-0165 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0437 ,Physics: 4D Treatment and DeliveryPTC58-0377 ,Physics: Quality Assurance and VerificationPTC58-0125 ,Physics: Quality Assurance and VerificationPTC58-0245 ,Physics: Dose Calculation and OptimisationPTC58-0337 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0334 ,Physics: Quality Assurance and VerificationPTC58-0121 ,General: New Horizons SessionPTC58-0563 ,General: New Horizons SessionPTC58-0321 ,Clinics: Head and Neck / EyePTC58-0477 ,Physics: Quality Assurance and VerificationPTC58-0480 ,Clinics: GUPTC58-0010 ,Clinics: EyePTC58-0684 ,Clinics: GUPTC58-0496 ,Clinics: Head and neckPTC58-0676 ,Clinics: GUPTC58-0137 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0256 ,Physics: 4D Treatment and DeliveryPTC58-0117 ,Physics: Absolute and Relative DosimetryPTC58-0552 ,Physics: Absolute and Relative DosimetryPTC58-0310 ,Physics: Absolute and Relative DosimetryPTC58-0672 ,Physics: Absolute and Relative DosimetryPTC58-0436 ,Physics: Dose Calculation and OptimisationPTC58-0452 ,Physics: Dose Calculation and OptimisationPTC58-0331 ,Physics: Commissioning New FacilitiesPTC58-0213 ,Biology: Mathematical Modelling SimulationPTC58-0272 ,Clinics: EyePTC58-0326 ,Physics: Commissioning New FacilitiesPTC58-0568 ,Physics: Dose Calculation and OptimisationPTC58-0444 ,Physics: Quality Assurance and VerificationPTC58-0379 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0095 ,Physics: Treatment PlanningPTC58-0053 ,Physics: Absolute and Relative DosimetryPTC58-0438 ,Physics: Absolute and Relative DosimetryPTC58-0317 ,Physics: Quality Assurance and VerificationPTC58-0497 ,Physics: Quality Assurance and VerificationPTC58-0375 ,Physics: Treatment PlanningPTC58-0056 ,Physics: 4D Treatment and DeliveryPTC58-0124 ,Clinics: GIPTC58-0009 ,Physics: Quality Assurance and VerificationPTC58-0014 ,Physics: Quality Assurance and VerificationPTC58-0374 ,Clinics: LungPTC58-0727 ,General: New Horizons SessionPTC58-0578 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0470 ,Clinics: LungPTC58-0204 ,Clinics: Head and neckPTC58-0227 ,Clinics: LungPTC58-0446 ,Physics: Quality Assurance and VerificationPTC58-0190 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0609 ,Clinics: LungPTC58-0689 ,General: New HorizonsPTC58-0021 ,General: New HorizonsPTC58-0262 ,Biology: BNCT Poster Discussion SessionsPTC58-0081 ,Clinics: GIPTC58-0726 ,General: New HorizonsPTC58-0145 ,Physics: Image GuidancePTC58-0573 ,General: New HorizonsPTC58-0027 ,General: New HorizonsPTC58-0028 ,Biology: Mathematical Modelling and SimulationPTC58-0148 ,Physics: Dose Calculation and OptimisationPTC58-0635 ,Physics: Image GuidancePTC58-0215 ,Physics: Image GuidancePTC58-0336 ,Poster AbstractsClinics: CNSPTC58-0535 ,Physics: Quality Assurance and VerificationPTC58-0187 ,Biology: BNCT Poster Discussion SessionsPTC58-0084 ,General: New Investigator SessionPTC58-0339 ,General: New Horizons SessionPTC58-0420 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0523 ,Biology: BNCT Poster Discussion SessionsPTC58-0088 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0112 ,Physics: Quality Assurance and VerificationPTC58-0182 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0615 ,Physics: Quality Assurance and VerificationPTC58-0080 ,Biology: BNCTPTC58-0085 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0722 ,General: New HorizonsPTC58-0253 ,General: New HorizonsPTC58-0255 ,Clinics: PediatricPTC58-0703 ,General: New HorizonsPTC58-0499 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0380 ,General: New HorizonsPTC58-0259 ,Clinics: GI, GU, BreastPTC58-0288 ,Clinics: GI, GU, BreastPTC58-0045 ,Physics: Absolute and Relative DosimetryPTC58-0619 ,Clinics: PediatricPTC58-0707 ,Physics: Quality Assurance and VerificationPTC58-0196 ,Physics: Quality Assurance and VerificationPTC58-0074 ,Physics: Quality Assurance and VerificationPTC58-0077 ,Biology: BNCT Poster Discussion SessionsPTC58-0073 ,Biology: BNCTPTC58-0075 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0093 ,Clinics: GUPTC58-0161 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0371 ,Physics: Monitoring and Modelling MotionPTC58-0181 ,General: New HorizonsPTC58-0120 ,General: New HorizonsPTC58-0362 ,General: New HorizonsPTC58-0364 ,Physics: Image GuidancePTC58-0473 ,Scientific: RTTPTC58-0641 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0296 ,General: New HorizonsPTC58-0004 ,General: New HorizonsPTC58-0128 ,Clinics: BreastPTC58-0316 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0236 ,General: New HorizonsPTC58-0008 ,General: New Investigator SessionPTC58-0673 ,Physics: Quality Assurance and VerificationPTC58-0167 ,Physics: Quality Assurance and VerificationPTC58-0289 ,Physics: Quality Assurance and VerificationPTC58-0284 ,General: New Horizons SessionPTC58-0522 ,Physics: Quality Assurance and VerificationPTC58-0164 ,Physics: Quality Assurance and VerificationPTC58-0285 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0623 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0502 ,Clinics: GUPTC58-0293 ,Biology: Translational and BiomarkersPTC58-0599 ,Biology: BNCTPTC58-0063 ,Clinics: LungPTC58-0656 ,General: New HorizonsPTC58-0592 ,Biology: BNCT Poster Discussion SessionsPTC58-0092 ,Poster AbstractsClinics: CNSPTC58-0302 ,Physics: Image GuidancePTC58-0464 ,General: New HorizonsPTC58-0352 ,Physics: Image GuidancePTC58-0465 ,General: New HorizonsPTC58-0476 ,Physics: Image GuidancePTC58-0100 ,General: New HorizonsPTC58-0235 ,Biology: Mathematical Modelling and SimulationPTC58-0349 ,Physics: Treatment PlanningPTC58-0094 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0367 ,Physics: Dose Calculation and OptimisationPTC58-0400 ,Biology: Translational and BiomarkersPTC58-0244 ,Physics: Dose Calculation and OptimisationPTC58-0640 ,Biology: Mathematical Modelling and SimulationPTC58-0355 ,General: New Investigator SessionPTC58-0320 ,Physics: Quality Assurance and VerificationPTC58-0057 ,Physics: Quality Assurance and VerificationPTC58-0174 ,Physics: Quality Assurance and VerificationPTC58-0295 ,Physics: Dose Calculation and OptimisationPTC58-0529 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0123 ,Physics: Quality Assurance and VerificationPTC58-0171 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0049 ,Clinics: BreastPTC58-0731 ,General: New HorizonsPTC58-0223 ,General: New HorizonsPTC58-0102 ,General: New HorizonsPTC58-0466 ,Scientific: RTTPTC58-0503 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0389 ,General: New HorizonsPTC58-0108 ,General: New HorizonsPTC58-0109 ,Physics: Commissioning New FacilitiesPTC58-0736 ,Biology: Mathematical Modelling and SimulationPTC58-0343 ,Biology: Mathematical Modelling and SimulationPTC58-0342 ,Clinics: GI, GU, BreastPTC58-0237 ,Physics: Dose Calculation and OptimisationPTC58-0711 ,Biology: Mathematical Modelling and SimulationPTC58-0581 ,Clinics: GI, GU, BreastPTC58-0114 ,Clinics: Base of SkullPTC58-0730 ,Clinics: Head and neckPTC58-0383 ,Clinics: CNS / Skull BasePTC58-0559 ,Clinics: Base of SkullPTC58-0613 ,General: New HorizonsPTC58-0691 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0054 ,General: New HorizonsPTC58-0210 ,Clinics: BreastPTC58-0729 ,General: New HorizonsPTC58-0574 ,Clinics: GI, GU, BreastPTC58-0239 ,Scientific: RTTPTC58-0637 ,General: New HorizonsPTC58-0579 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0176 ,General: New HorizonsPTC58-0699 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0156 ,Biology: Mathematical Modelling and SimulationPTC58-0333 ,Biology: Translational and BiomarkersPTC58-0345 ,Physics: Image GuidancePTC58-0369 ,Physics: Commissioning New FacilitiesPTC58-0509 ,Biology: Mathematical Modelling SimulationPTC58-0658 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0051 ,General: New Investigator SessionPTC58-0548 ,Clinics: GI, GU, BreastPTC58-0241 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0412 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0024 ,Clinics: LungPTC58-0226 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0069 ,General: New HorizonsPTC58-0562 ,General: New HorizonsPTC58-0561 ,General: New HorizonsPTC58-0201 ,Biology: Mathematical Modelling and SimulationPTC58-0439 ,General: New HorizonsPTC58-0445 ,General: New HorizonsPTC58-0324 ,Physics: Image GuidancePTC58-0031 ,Biology: Mathematical Modelling and SimulationPTC58-0558 ,Physics: Image GuidancePTC58-0392 ,Biology: Mathematical Modelling and SimulationPTC58-0678 ,Physics: Beam Delivery and Nozzle DesignPTC58-0090 ,General: New Investigator SessionPTC58-0630 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0524 ,Physics: Commissioning New FacilitiesPTC58-0713 ,Clinics: GI, GU, BreastPTC58-0139 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0248 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0368 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0519 ,General: New Horizons SessionPTC58-0720 ,Physics: Quality Assurance and VerificationPTC58-0083 ,General: New HorizonsPTC58-0311 ,General: New HorizonsPTC58-0674 ,General: New HorizonsPTC58-0553 ,Physics: Image GuidancePTC58-0023 ,Scientific: RTTPTC58-0612 ,General: New HorizonsPTC58-0677 ,Biology: Mathematical Modelling and SimulationPTC58-0545 ,Physics: Dose Calculation and OptimisationPTC58-0601 ,Physics: Dose Calculation and OptimisationPTC58-0725 ,Physics: Quality Assurance and VerificationPTC58-0098 ,Physics: Dose Calculation and OptimisationPTC58-0605 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0517 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0618 ,Physics: Monitoring and Modelling MotionPTC58-0481 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0071 ,Physics: Adaptive TherapyPTC58-0351 ,Physics: 4D Treatment and DeliveryPTC58-0702 ,Physics: Image GuidancePTC58-0734 ,Physics: Image GuidancePTC58-0611 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0486 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0442 ,Biology: Drug and Immunotherapy CombinationsPTC58-0327 ,Clinics: Head and Neck / EyePTC58-0096 ,Clinics: LungPTC58-0159 ,Physics: Treatment PlanningPTC58-0708 ,General: New HorizonsPTC58-0097 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0350 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0016 ,Physics: Adaptive TherapyPTC58-0104 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0433 ,Physics: Image GuidancePTC58-0608 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0610 ,Clinics: Head and neckPTC58-0058 ,Physics: Treatment PlanningPTC58-0715 ,Clinics: Head and neckPTC58-0298 ,Clinics: EyePTC58-0099 ,General: New HorizonsPTC58-0086 ,General: New HorizonsPTC58-0089 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0200 ,Poster AbstractsClinics: CNSPTC58-0157 ,Clinics: LungPTC58-0141 ,Clinics: LungPTC58-0260 ,Clinics: LungPTC58-0264 ,Physics: Image GuidancePTC58-0513 ,Physics: Image GuidancePTC58-0631 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0469 ,Biology: BNCT Poster Discussion SessionsPTC58-0384 ,Physics: Image GuidancePTC58-0639 ,Clinics: PediatricsPTC58-0700 ,Clinics: LungPTC58-0136 ,Clinics: BreastPTC58-0706 ,General: New HorizonsPTC58-0079 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0406 ,Clinics: Base of SkullPTC58-0382 ,Physics: Image GuidancePTC58-0624 ,Physics: Beam Delivery and Nozzle DesignPTC58-0173 ,Biology: Drug and Immunotherapy CombinationsPTC58-0358 ,Poster AbstractsClinics: CNSPTC58-0690 ,General: New HorizonsPTC58-0061 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0580 ,Physics: Monitoring and Modelling MotionPTC58-0162 ,Physics: Adaptive TherapyPTC58-0550 ,Physics: Adaptive TherapyPTC58-0430 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0103 ,General: New Investigator SessionPTC58-0252 ,Physics: Quality Assurance and VerificationPTC58-0704 ,Physics: Image GuidancePTC58-0418 ,Clinics: Base of SkullPTC58-0572 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0106 ,Physics: Beam Delivery and Nozzle DesignPTC58-0022 ,Physics: Monitoring and Modelling MotionPTC58-0279 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0447 ,Physics: Treatment PlanningPTC58-0622 ,Clinics: PediatricsPTC58-0644 ,Biology: Biology and Clinical InterfacePTC58-0490 ,Clinics: CNS / Skull BasePTC58-0716 ,General: New HorizonsPTC58-0292 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0570 ,General: New HorizonsPTC58-0059 ,Physics: Quality Assurance and VerificationPTC58-0710 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0216 ,Physics: Image GuidancePTC58-0404 ,Physics: Image GuidancePTC58-0525 ,Physics: Image GuidancePTC58-0526 ,Poster AbstractsClinics: CNSPTC58-0328 ,Clinics: LungPTC58-0070 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0135 ,Biology: BNCT Poster Discussion SessionsPTC58-0391 ,Physics: Treatment PlanningPTC58-0510 ,Physics: Treatment PlanningPTC58-0636 ,Physics: Treatment PlanningPTC58-0638 ,Physics: Image GuidancePTC58-0408 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0632 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0318 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0246 ,Clinics: PediatricsPTC58-0504 ,General: New HorizonsPTC58-0160 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0076 ,Physics: Monitoring and Modelling MotionPTC58-0143 ,Biology: Mathematical Modelling and SimulationPTC58-0718 ,Physics: Image GuidancePTC58-0671 ,Clinics: LungPTC58-0183 ,Physics: Image GuidancePTC58-0670 ,Report ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0422 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0129 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0705 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0258 ,General: New HorizonsPTC58-0030 ,General: New HorizonsPTC58-0150 ,Biology: Biology and Clinical InterfacePTC58-0479 ,General: New HorizonsPTC58-0153 ,Clinics: PediatricPTC58-0087 ,General: New HorizonsPTC58-0152 ,General: New HorizonsPTC58-0155 ,General: New HorizonsPTC58-0033 ,General: New HorizonsPTC58-0158 ,Physics: Image GuidancePTC58-0429 ,Biology: Translational and BiomarkersPTC58-0287 ,Physics: Adaptive TherapyPTC58-0403 ,Physics: Image GuidancePTC58-0309 - Published
- 2020
8. Imaging Features with Histopathologic Correlation of CNS High-Grade Neuroepithelial Tumors with a BCOR Internal Tandem Duplication
- Author
-
Cardoen, L., primary, Tauziède-Espariat, A., additional, Dangouloff-Ros, V., additional, Moalla, S., additional, Nicolas, N., additional, Roux, C.-J., additional, Bouchoucha, Y., additional, Bourdeaut, F., additional, Beccaria, K., additional, Bolle, S., additional, Pierron, G., additional, Dufour, C., additional, Doz, F., additional, Boddaert, N., additional, and Brisse, H.J., additional
- Published
- 2021
- Full Text
- View/download PDF
9. Prognostic and therapeutic biomarkers in a series of 33 pediatric chordomas: O14
- Author
-
Tauziède-Espariat, A., Beccaria, K., Monnieni, F., Adle-Biassette, H., Masliah-Planchon, J., Polivka, M., Laquerrière, A., Bouillot-Eimer, S., Gauchotte, G., Sevestre, H., Puget, S., and Varlet, P.
- Published
- 2016
10. Imaging features of medulloblastoma: Conventional imaging, diffusion-weighted imaging, perfusion-weighted imaging, and spectroscopy: From general features to subtypes and characteristics
- Author
-
Dangouloff-Ros, V., primary, Varlet, P., additional, Levy, R., additional, Beccaria, K., additional, Puget, S., additional, Dufour, C., additional, and Boddaert, N., additional
- Published
- 2021
- Full Text
- View/download PDF
11. Imaging Features with Histopathologic Correlation of CNS High-Grade Neuroepithelial Tumors with a BCOR Internal Tandem Duplication.
- Author
-
Cardoen, L., Tauziède-Espariat, A., Dangouloff-Ros, V., Moalla, S., Nicolas, N., Roux, C.-J., Bouchoucha, Y., Bourdeaut, F., Beccaria, K., Bolle, S., Pierron, G., Dufour, C., Doz, F., Boddaert, N., and Brisse, H. J.
- Published
- 2022
- Full Text
- View/download PDF
12. Focal Areas of High Signal Intensity in Children with Neurofibromatosis Type 1: Expected Evolution on MRI
- Author
-
Calvez, S., primary, Levy, R., additional, Calvez, R., additional, Roux, C.-J., additional, Grévent, D., additional, Purcell, Y., additional, Beccaria, K., additional, Blauwblomme, T., additional, Grill, J., additional, Dufour, C., additional, Bourdeaut, F., additional, Doz, F., additional, Robert, M.P., additional, Boddaert, N., additional, and Dangouloff-Ros, V., additional
- Published
- 2020
- Full Text
- View/download PDF
13. Hydrocéphalie après rupture de malformation artério-veneuse cérébrale chez l’enfant
- Author
-
Stricker, S., primary, Boulouis, G., additional, Benichi, S., additional, Gariel, F., additional, Garzelli, L., additional, Beccaria, K., additional, Chivet, A., additional, de Saint Denis, T., additional, James, S., additional, Paternoster, G., additional, Zerah, M., additional, Bourgeois, M., additional, Boddaert, N., additional, Brunelle, F., additional, Meyer, P., additional, Puget, S., additional, Naggara, O., additional, and Blauwblomme, T., additional
- Published
- 2020
- Full Text
- View/download PDF
14. Clinical, Radiological, Histopathological, Molecular Description and Identification of Prognostic Factors for Desmoplastic Infantile Gangliogliomas and Astrocytomas: A Multicentric Cohort Study
- Author
-
Gourmel, A., Perbet, R., Beccaria, K., Maurage, C. A., Escande, F., Grill, J., Varlet, P., Figarella, D., Vinchon, M., Bourdeaut, F., Devoldere, C., Le Moing, Anne Gaelle, Salamon, A. I. Bertozzi, de Carli, E., Gentet, J. C., Icher, C., Frappaz, D., Silva, K., Leblond, P., Service de pathologie [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy], Institut Gustave Roussy (IGR), Vectorologie et thérapeutiques anti-cancéreuses [Villejuif] (UMR 8203), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Anatomo-Cyto-Pathologie et de NeuroPathologie [Hôpital de la Timone - APHM] (ACPNP), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Amiens-Picardie, Groupe de Recherche sur l'Analyse Multimodale de la Fonction Cérébrale - UMR INSERM_S 1105 (GRAMFC), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Léon Bérard [Lyon], Dynamique des Génomes et Adaptation Microbienne (DynAMic), Institut National de la Recherche Agronomique (INRA)-Université de Lorraine (UL), and DESSAIVRE, Louise
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2019
15. Chapitre 93 - Pathologies neurochirurgicales
- Author
-
Puget, S. and Beccaria, K.
- Published
- 2016
- Full Text
- View/download PDF
16. Ouverture transitoire de la barrière hémato-médullaire de lapin par ultrasons pulsés de faible intensité
- Author
-
Montero, A.-S., primary, Bielle, F., additional, Goldwirth, L., additional, Lalot, A., additional, Beccaria, K., additional, Pradat, P.-F., additional, Salachas, F.S., additional, and Carpentier, A., additional
- Published
- 2018
- Full Text
- View/download PDF
17. NSRG-05. SAFETY OF ULTRASOUND-INDUCED BLOOD-BRAIN BARRIER OPENING IN PEDIATRIC PATIENTS WITH REFRACTORY SUS-TENTORIAL MALIGNANT BRAIN TUMORS BEFORE CHEMOTHERAPY ADMINISTRATION – THE SONOKID CLINICAL TRIAL
- Author
-
Beccaria, K, primary, Canney, M, additional, Bouchoux, G, additional, Zohar, S, additional, Boddaert, N, additional, Bourdeaut, F, additional, Doz, F, additional, Dufour, C, additional, Grill, J, additional, Carpentier, A, additional, and Puget, S, additional
- Published
- 2018
- Full Text
- View/download PDF
18. Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?
- Author
-
Lobon-Iglesias, M. J., primary, Giraud, G., additional, Castel, D., additional, Philippe, C., additional, Debily, M. A., additional, Briandet, C., additional, Fouyssac, F., additional, de Carli, E., additional, Dufour, C., additional, Valteau-Couanet, D., additional, Sainte-Rose, C., additional, Blauwblomme, T., additional, Beccaria, K., additional, Zerah, M., additional, Puget, S., additional, Calmon, R., additional, Boddaert, N., additional, Bolle, S., additional, Varlet, P., additional, and Grill, J., additional
- Published
- 2017
- Full Text
- View/download PDF
19. Gangliogliomes de fosse postérieure : résultats d’une série de 36 enfants et revue de la littérature
- Author
-
Puget, S., primary, Alshehri, A., additional, Beccaria, K., additional, Blauwblomme, T., additional, Paternoster, G., additional, de Saint Denis, T., additional, James, S., additional, Dufour, C., additional, Bourdeault, F., additional, Varlet, P., additional, Sainte-Rose, C., additional, and Zérah, M., additional
- Published
- 2017
- Full Text
- View/download PDF
20. À propos d’une série de 33 chordomes pédiatriques : validation du score immunohistopronostique et établissement d’un nouvel algorithme pronostique intégrant le statut SMARCB1
- Author
-
Tauziède-Espariat, A., primary, Adle-Biassette, H., additional, Polivka, M., additional, Beccaria, K., additional, Puget, S., additional, Laquerrière, A., additional, Sevestre, H., additional, Gauchotte, G., additional, Eimer, S., additional, Masliah-Planchon, J., additional, and Varlet, P., additional
- Published
- 2016
- Full Text
- View/download PDF
21. Tumeur pinéales : à propos d’une série de 101 cas pédiatriques
- Author
-
Chivoret, N., primary, Varlet, P., additional, Dufour, C., additional, Boddaert, N., additional, Blauwblomme, T., additional, Beccaria, K., additional, Zerah, M., additional, Sainte-Rose, C., additional, and Puget, S., additional
- Published
- 2014
- Full Text
- View/download PDF
22. Ouverture de la barrière hémato-encéphalique par un dispositif ultrasonore implantable : résultats pré-cliniques sur primates et résultats préliminaires de l’essai clinique SonoCloud de phase I/Iia
- Author
-
Carpentier, A., primary, Canney, M., additional, Horodyckid, C., additional, Leclercq, D., additional, Vignot, A., additional, Beccaria, K., additional, Boisgard, R., additional, Goldwirt, L., additional, Reina, V., additional, Lafon, C., additional, Chapelon, J., additional, Capelle, L., additional, Dehais, C., additional, Cornu, P., additional, Delattre, J., additional, and Idbaih, A., additional
- Published
- 2014
- Full Text
- View/download PDF
23. Kystes supra-sellaires de l’enfant : une série de 36 cas
- Author
-
André, A., primary, Zerah, M., additional, Paternoster, G., additional, Beccaria, K., additional, Blauwblomme, T., additional, Puget, S., additional, Sainte-Rose, C., additional, and Di Rocco, F., additional
- Published
- 2014
- Full Text
- View/download PDF
24. Les auteurs
- Author
-
Abbal, J., Alison, M., Assouline, C., Aubry, E., Aujard, Y., Barjol, A., Baud, O., Beccaria, K., Bednarek, N., Benachi, A., Bénard, M., Benoist, J.-F., Berrebi, A., Besson, R., Bingen, E.<ce:sup loc='post">†</ce:sup>, Blanchard, B., Boileau, P., Bonnet, M.-P., Bonsante, F., Boudred, F., Bouvattier, C., Broué, P., Buffin, R., Cambonie, G., Caputo, G., Carbonne, B., Casper, C., Chabernaud, J.-L., Champion, V., Chantepie, A., Chollat, C., Claris, O., Cortey, A., Dageville, C., Dauger, S., de Halleux, V., de Lagausie, P., Debillon, T., Decobert, F., Delacourt, C., Delanoë, C., Delezoide, A.-L., Desenfant, A., Desfrère, L., Desprez, P., Dupont, C., Durrmeyer, X., Elmaleh-Bergès, M., Epaud, R., Favrais, G., Fayoux, P., Fesseau, R., Flamein, F., Garnier, A., Godde, F., Gournay, V., Gouyon, J.-B., Gras-le Guen, C., Gremmo-Féger, G., Gressens, P., Groussolles, M., Guignard, J.-P., Guimiot, F., Hadj-Rabia, S., Hascoët, J.-M., Hays, S., Houeijeh, A., Iacobelli, S., Jacquot, A., Jarreau, P.-H., Jourdain, G., Jourdes, E., Kermorvant, E., Keszlick, A., Khen-Dunlop, N., Khung-Savatovsky, S., Kuhn, P., Labarthe, F., Lahoche Manucci, A., Laprugne-Garcia, É., Launay, E., Le Saché, N., Lepercq, J., Lescure, S., Ligi, I., Lopez, C., Lopez, E., Magny, J.-F., Maisonneuve, E., Marret, S., Messer, J., Mezger, V., Milési, C., Mitanchez, D., Montjaux-Régis, N., Morau, E., Moriette, G., Mur, S., Norbert, K., Parain, D., Parat, S., Pariente, D., Patkai, J., Pennaforte, T., Picaud, J.-C., Pieltain, C., Pinto-Cardoso, G., Pognon, L., Priso, R.H., Puget, S., Rakza, T., Rasigade, J.-P., Rigo, J., Rozé, J.-C., Saint Frison, M.-H., Saliba, E., Salomon, L.-J., Savajols, E., Schang, A.-L., Schmitz, T., Sebag, G.<ce:sup loc='post">†</ce:sup>, Semama Denis, S., Senterre, Th., Servais, L., Sharma, D., Simeoni, U., Storme, L., Tanase, A., Tardieu, M., Tissières, P., Touzet, M., Tréluyer, J.-M., Tricoire, J., Truffert, P., Tsatsaris, V., Ulinski, T., Van Steenwinckel, J., Venot, P., Vincent, A., Wallach, D., and Zana-Taïeb, E.
- Published
- 2016
- Full Text
- View/download PDF
25. Post-zygotic mosaicism of SMARCB1 variants in patients with rhabdoid tumors: a not so rare condition exposing to successive tumors.
- Author
-
Thomson G, Filser M, Guerrini-Rousseau L, Tauziede-Espariat A, Bourneix C, Gauthier-Villars M, Simaga F, Beccaria K, Faure-Conter C, Maureille A, Zattara-Cannoni H, Andre N, Entz-Werle N, Brugieres L, Mansuy L, Denizeau P, Julia S, Ingster O, Lejeune S, Brahimi A, Coupier I, Bonadona V, Delattre O, Masliah-Planchon J, and Bourdeaut F
- Abstract
Background: Rhabdoid tumors (RT) are aggressive, rare tumors predominantly affecting young children, characterized by bi-allelic SMARCB1 gene inactivation. While most SMARCB1 alterations are acquired de novo, a third of cases exhibit germline alterations, defining Rhabdoid Tumors Predisposition Syndrome (RTPS1). With increased sensitivity of next-generation sequencing (NGS), mosaicisms in genes linked to genetic diseases are more detectable. This study focuses on exploring SMARCB1 germline alterations, notably mosaicism in blood samples of children with RT and in parents, using a custom NGS panel., Methods: A cohort of 280 children and 140 parents with germline analysis was studied. Germline DNA from 111 children with RT and 32 parents were re-analyzed with a custom NGS panel with 1,500X average depth targeting the SMARCB1 gene to identify intragenic variants not detected with conventional low-sensitivity methods. Follow-up data was obtained for 77 patients., Results: Nine previously undetected mosaicism cases were identified, totaling 17/280 patients with a mosaic variant (6.1%) in the cohort, with variant allele frequencies between 0.9% and 33%, thus highlighting the prior underestimation of its prevalence. Follow-up data showed that 4 out of 7 survivors with mosaic variants developed distinct novel tumors, two sharing SMARCB1 alterations with the initial tumor, emphasizing the potential clinical impact of SMARCB1 mosaicism., Conclusions: The hitherto underestimated rate of SMARCB1 mosaicism in RT underscores the need for optimized genetic counseling and oncological monitoring. The findings have significant medical implications, considering the dire prognosis of RT., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
26. Supra-tentorial Ependymomas with ZFTA Fusion, YAP1 Fusion, and Astroblastomas, MN1-altered: Characteristic Imaging Features.
- Author
-
Perrod V, Levy R, Tauziède-Espariat A, Roux CJ, Beccaria K, Blauwblomme T, Grill J, Dufour C, Guerrini-Rousseau L, Abbou S, Bolle S, Roux A, Pallud J, Provost C, Oppenheim C, Varlet P, Boddaert N, and Dangouloff-Ros V
- Abstract
Purpose: Supratentorial (ST) ependymoma subgroups are defined by two different fusions with different prognoses. Astroblastomas, MN1-altered, have ependymal-like histopathologic features and represent a differential diagnosis in children. We hypothesized that ZFTA-fused ependymoma and YAP1-fused ependymoma on the one hand, and astroblastoma, MN1-altered, on the other hand, show different MRI characteristics., Methods: We retrospectively analyzed the preoperative imaging of 45 patients with ST ependymoma or astroblastoma between January 2000 and September 2020, blinded to histomolecular grouping. Several characteristics, such as location, tumor volume, calcifications, solid/cystic component, and signal enhancement or diffusion were evaluated. We compared imaging characteristics according to their molecular subtype (ZFTA-fused, YAP1-fused, and astroblastoma, MN1-altered)., Results: Thirty-nine patients were classified as having an ependymoma, 35 with a ZFTA fusion and four with a YAP1 fusion, and six as having an astroblastoma, MN1-altered. YAP1-fused ependymomas were more likely to involve at least 3 lobes than ZFTA-fused ependymomas. Astroblastomas were located in the frontal lobe in 100% of the tumors versus 49% of the ependymomas. Cerebral blood flow by arterial spin labeling was higher in astroblastomas than in ependymomas. There were no differences in the other characteristics between the molecular groups. All the tumors showed common features: intra-axial extra-ventricular tumors, very frequent contrast enhancement (39/43, 91%), a cystic/necrotic component (41/45, 91%), restricted diffusion (32/36, 89%), calcifications (15/18, 83%), and peri-tumoral edema (38/44, 86%)., Conclusion: The distinction between ST ependymoma subtypes and astroblastomas can be guided by several imaging features. These tumors share common imaging features that may help to differentiate ST ependymomas and astroblastomas from other pediatric ST tumors., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
- Published
- 2024
- Full Text
- View/download PDF
27. Glioma oncogenesis in the Constitutional mismatch repair deficiency (CMMRD) syndrome.
- Author
-
Guerrini-Rousseau L, Merlevede J, Denizeau P, Andreiuolo F, Varlet P, Puget S, Beccaria K, Blauwblomme T, Cabaret O, Hamzaoui N, Bourdeaut F, Faure-Conter C, Muleris M, Colas C, Adam de Beaumais T, Castel D, Rouleau E, Brugières L, Grill J, and Debily MA
- Abstract
Background: Constitutional mismatch repair deficiency (CMMRD) is a cancer predisposition due to biallelic mutations in one of the mismatch repair (MMR) genes associated with early onset of cancers, especially high-grade gliomas. Our aim was to decipher the molecular specificities of these gliomas., Methods: Clinical, histopathological, and whole exome sequencing data were analyzed in 12 children with genetically proven CMMRD and a high-grade glioma., Results: PDL1 expression was present in immunohistochemistry in 50% of the samples. In 9 patients, the glioma harbored an ultra-hypermutated phenotype (104-635 coding single nucleotide variants (SNV) per Mb, median 204). Driver mutations in POLE and POLD1 exonuclease domains were described for 8 and 1 patients respectively and were always present in the mutation burst with the highest variant allele frequency (VAF). The mutational signatures were dominated by MMR-related ones and similar in the different mutation bursts of a same patient without subsequent enrichment of the mutation signatures with POL-driven ones. Median number of coding SNV with VAF above one of the driving polymerase mutation per Mb was 57 (17-191). Our findings suggest that somatic polymerase alterations does not entirely explain the ultra-hypermutant phenotype. SETD2 , TP53 , NF1 , EPHB2 , PRKDC, and DICER1 genes were frequently mutated with higher VAF than the deleterious somatic polymerase mutation., Conclusions: CMMRD-associated gliomas have a specific oncogenesis that does not involve usual pathways and mutations seen in sporadic pediatric or adult glioblastomas. Frequent alterations in other pathways such as MAPK may suggest the use of other targeted therapies along with PD1 inhibitors., Competing Interests: The authors have no commercial association that might pose or create the appearance of a conflict of interest with the information presented in the submitted manuscript., (© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
28. Specific brain MRI features of constitutional mismatch repair deficiency syndrome in children with high-grade gliomas.
- Author
-
Raveneau M, Guerrini-Rousseau L, Levy R, Roux CJ, Bolle S, Doz F, Bourdeaut F, Colas C, Blauwblomme T, Beccaria K, Tauziède-Espariat A, Varlet P, Dufour C, Grill J, Boddaert N, and Dangouloff-Ros V
- Abstract
Background: Children with constitutional mismatch repair deficiency (CMMRD) syndrome have an increased risk of high-grade gliomas (HGG), and brain imaging abnormalities. This study analyzes brain imaging features in CMMRD syndrome children versus those with HGG without CMMRD., Methods: Retrospective comparative analysis of brain imaging in 30 CMMRD children (20 boys, median age eight years, 22 with HGG), seven with Lynch syndrome (7 HGG), 39 with type 1 neurofibromatosis (NF1) (four with HGG) and 50 with HGG without MMR or NF1 pathogenic variant ("no-predisposition" patients)., Results: HGG in CMMRD and Lynch patients were predominantly hemispheric (versus midline) compared to NF1 and no-predisposition patients (91% and 86%, vs 25% and 54%, p = 0.004). CMMRD-associated tumors often had ill-defined boundaries (p = 0.008). All CMMRD patients exhibited at least one developmental venous anomaly (DVA), versus 14%, 10%, and 6% of Lynch, NF1, and no-predisposition patients (p < 0.0001). Multiple DVAs were observed in 83% of CMMRD patients, one NF1 patient (3%), and never in other groups (p < 0.0001). Cavernomas were discovered in 21% of CMMRD patients, never in other groups (p = 0.01). NF1-like focal areas of high T2-FLAIR signal intensity (FASI) were more prevalent in CMMRD patients than in Lynch or no-predisposition patients (50%, vs 20% and 0%, respectively, p < 0.0001). Subcortical and ill-limited FASI, possibly involving the cortex, were specific to CMMRD (p < 0.0001) and did not evolve in 93% of patients (13/14)., Conclusion: Diffuse hemispherically located HGG associated with multiple DVAs, cavernomas, and NF1-like or subcortical FASI strongly suggests CMMRD syndrome compared to children with HGG in other contexts., Clinical Relevance Statement: The radiologic suggestion of CMMRD syndrome when confronted with HGGs in children may prompt genetic testing. This can influence therapeutic plans. Therefore, imaging features could potentially be incorporated into CMMRD testing recommendations., Key Points: Using imaging to detect CMMRD syndrome early may improve patient care. CMMRD features include: hemispheric HGG with multiple developmental venous anomalies and NF1-like or subcortical areas with high T2-FLAIR intensity. We propose novel imaging features to improve the identification of potential CMMRD patients., (© 2024. The Author(s), under exclusive licence to European Society of Radiology.)
- Published
- 2024
- Full Text
- View/download PDF
29. Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.
- Author
-
Morin A, Allodji R, Kariyawasam D, Touraine P, Puget S, Beccaria K, De Carli E, Kieffer V, Rivollet S, Abbou S, Fayech C, Souchard V, Dufour C, De Vathaire F, Bolle S, Grill J, and Fresneau B
- Subjects
- Humans, Male, Female, Child, Child, Preschool, Adolescent, Longitudinal Studies, Follow-Up Studies, Survival Rate, Cancer Survivors statistics & numerical data, Infant, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local epidemiology, Prognosis, Adult, Neurofibromatosis 1 therapy, Neurofibromatosis 1 complications, Neurofibromatosis 1 mortality, Neurofibromatosis 1 pathology, Infant, Newborn, Optic Nerve Glioma pathology, Optic Nerve Glioma therapy
- Abstract
Background: Optic pathway gliomas (OPGs) represent 5% of childhood brain tumors. Successive relapses lead to multiple treatments exposing to late complications., Methods: We included patients treated at Gustave Roussy (GR) between January 1980 and December 2015 for OPG, before 18 years old and alive at 5 years from diagnosis. Mortality and physical health conditions data were extracted from medical data files and updated, thanks to the GR long-term follow-up program and French national mortality registry for patients included in the French Childhood Cancer Survivor Study., Results: We included 182 5-year OPG-childhood survivors in the analysis (sex ratio M/F 0.8, 35% with neurofibromatosis type 1 [NF1]). With a median follow-up of 17.2 years (range = 5-41), we registered 82 relapses, 9 second malignancies, and 15 deaths as first events after 5 years, resulting in 20-year conditional overall survival (C-OS) and late events-free survival of 79.9% (95% confidence interval [CI] = 71-86) and 43.5% (95% CI = 36-51), respectively. Radiotherapy exposure in NF1 patients (hazard ratio [HR] = 6, 95% CI = 1.7-21.2) and hypothalamic involvement (HR = 3.2, 95% CI = 1.4-7.3) were significantly associated with C-OS in multivariable analyses. Ninety-five percent of 5-year OPG survivors suffered from any health condition, especially visual acuity "<1/10" (n = 109), pituitary deficiency (n = 106), and neurocognitive impairment (n = 89). NF1 (HR 2.1) was associated with precocious puberty. With a median time post-diagnosis of 4.2 years, 33 cerebrovascular events were observed in 21 patients., Conclusions: Late relapses, second malignancies, and cerebrovascular diseases are severe late events resulting in premature mortality. Morbidity is high and needs after-cancer care to improve quality of life. Risk factors could be considered to better stratify long-term follow-up., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
30. Medulloblastomas with ELP1 pathogenic variants: A weakly penetrant syndrome with a restricted spectrum in a limited age window.
- Author
-
Guerrini-Rousseau L, Masliah-Planchon J, Filser M, Tauziède-Espariat A, Entz-Werle N, Maugard CM, Hopman SMJ, Torrejon J, Gauthier-Villars M, Simaga F, Blauwblomme T, Beccaria K, Rouleau E, Dimaria M, Grill J, Abbou S, Claret B, Brugières L, Doz F, Bouchoucha Y, Faure-Conter C, Bonadona V, Mansuy L, de Carli E, Ingster O, Legrand C, Pagnier A, Berthet P, Bodet D, Julia S, Bertozzi AI, Wilems M, Maurage CA, Delattre O, Ayrault O, Dufour C, and Bourdeaut F
- Abstract
Background: ELP1 pathogenic variants (PV) have been recently identified as the most frequent variants predisposing to Sonic Hedgehog (SHH) medulloblastomas (MB); however, guidelines are still lacking for genetic counseling in this new syndrome., Methods: We retrospectively reviewed clinical and genetic data of a French series of 29 ELP1 -mutated MB., Results: All patients developed SHH-MB, with a biallelic inactivation of PTCH1 found in 24 tumors. Other recurrent alterations encompassed the TP53 pathway and activation of MYCN/MYCL signaling. The median age at diagnosis was 7.3 years (range: 3-14). ELP1 -mutated MB behave as sporadic cases, with similar distribution within clinical and molecular risk groups and similar outcomes (5 y - OS = 86%); no unusual side effect of treatments was noticed. Remarkably, a germline ELP1 PV was identified in all patients with available constitutional DNA ( n = 26); moreover, all tested familial trio ( n = 11) revealed that the PVs were inherited. Two of the 26 index cases from the French series had a family history of MB; pedigrees from these patients and from 1 additional Dutch family suggested a weak penetrance. Apart from MB, no cancer was associated with ELP1 PVs; second tumors reported in 4 patients occurred within the irradiation fields, in the usual time-lapse for expected radiotherapy-induced neoplasms., Conclusions: The low penetrance, the "at risk' age window limited to childhood and the narrow tumor spectrum, question the actual benefit of genetic screening in these patients and their family. Our results suggest restricting ELP1 germline sequencing to patients with SHH-MB, depending on the parents" request., Competing Interests: None declared., (© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
31. Long-term weight gain in children with craniopharyngioma.
- Author
-
Rovani S, Butler V, Samara-Boustani D, Pinto G, Gonzalez-Briceno L, Nguyen Quoc A, Vermillac G, Stoupa A, Besançon A, Beltrand J, Thalassinos C, Flechtner I, Dassa Y, Viaud M, Arrom-Branas MB, Boddaert N, Puget S, Blauwblomme T, Alapetite C, Bolle S, Doz F, Grill J, Dufour C, Bourdeaut F, Abbou S, Guerrini-Rousseau L, Leruste A, Beccaria K, Polak M, and Kariyawasam D
- Subjects
- Humans, Male, Female, Child, Retrospective Studies, Adolescent, Child, Preschool, Follow-Up Studies, Risk Factors, Hypothalamus, Cohort Studies, Craniopharyngioma epidemiology, Craniopharyngioma complications, Weight Gain physiology, Pituitary Neoplasms epidemiology, Pituitary Neoplasms pathology, Pituitary Neoplasms complications, Body Mass Index
- Abstract
Objective: Adamantinomatous craniopharyngioma mainly affects children. Excessive weight gain is a major long-term complication. The primary objective of this study was to assess long-term weight changes in children treated for craniopharyngioma. The secondary objectives were to identify risk factors for excessive weight gain and to look for associations with hypothalamic damage by the tumour or treatment., Design: Single-centre retrospective cohort study., Method: Children managed for craniopharyngioma at our centre between 1990 and 2019 were included. The body mass index (BMI) standard deviation scores (SDS) at baseline and at last follow-up were compared. Univariate and multivariate analyses were performed in order to identify variables associated with the long-term BMI-SDS variation., Results: The 108 patients had a mean follow-up of 10.4 years. The mean BMI-SDS increase over time was 2.11 (P < .001) overall, 1.21 (P < .001) in the group without hypothalamic involvement by the tumour, and 1.95 (P < .001) in the group managed using intended hypothalamus-sparing surgery. The absence of hypothalamic involvement by the tumour or treatment was significantly associated with less weight gain (P = .046 and P < .01, respectively). After adjustment, factors associated with a BMI-SDS change greater than 2 were female sex (P = .023), tumour involving the hypothalamus (P = .04), and higher baseline BMI (P < .001)., Conclusion: Clinically significant weight gain occurred in nearly all children treated for craniopharyngioma, including those whose hypothalamus was spared by the tumour and intentionally by treatment. However, hypothalamus integrity was associated with less weight gain. Despite hypothalamus-sparing strategies, hypothalamic obesity remains a major concern, indicating a need for novel treatment approaches., Competing Interests: Conflict of interest: The authors declare no conflict of interest., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology.)
- Published
- 2024
- Full Text
- View/download PDF
32. CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas.
- Author
-
Tauziède-Espariat A, Nicaise Y, Sievers P, Sahm F, von Deimling A, Guillemot D, Pierron G, Duchesne M, Edjlali M, Dangouloff-Ros V, Boddaert N, Roux A, Dezamis E, Hasty L, Lhermitte B, Hirsch E, Hirsch MPV, Ardellier FD, Karnoub MA, Csanyi M, Maurage CA, Mokhtari K, Bielle F, Rigau V, Roujeau T, Abad M, Klein S, Bernier M, Horodyckid C, Adam C, Brandal P, Niehusmann P, Vannod-Michel Q, Provost C, de Champfleur NM, Nichelli L, Métais A, Mariet C, Chrétien F, Blauwblomme T, Beccaria K, Pallud J, Puget S, Uro-Coste E, and Varlet P
- Subjects
- Child, Humans, Cell Cycle Proteins, In Situ Hybridization, Fluorescence, Transcription Factors genetics, Tumor Suppressor Proteins genetics, Brain Neoplasms genetics, Central Nervous System Neoplasms genetics, Ependymoma pathology, Glioma, Subependymal, Supratentorial Neoplasms pathology
- Abstract
A novel methylation class, "neuroepithelial tumor, with PLAGL1 fusion" (NET-PLAGL1), has recently been described, based on epigenetic features, as a supratentorial pediatric brain tumor with recurrent histopathological features suggesting an ependymal differentiation. Because of the recent identification of this neoplastic entity, few histopathological, radiological and clinical data are available. Herein, we present a detailed series of nine cases of PLAGL1-fused supratentorial tumors, reclassified from a series of supratentorial ependymomas, non-ZFTA/non-YAP1 fusion-positive and subependymomas of the young. This study included extensive clinical, radiological, histopathological, ultrastructural, immunohistochemical, genetic and epigenetic (DNA methylation profiling) data for characterization. An important aim of this work was to evaluate the sensitivity and specificity of a novel fluorescent in situ hybridization (FISH) targeting the PLAGL1 gene. Using histopathology, immunohistochemistry and electron microscopy, we confirmed the ependymal differentiation of this new neoplastic entity. Indeed, the cases histopathologically presented as "mixed subependymomas-ependymomas" with well-circumscribed tumors exhibiting a diffuse immunoreactivity for GFAP, without expression of Olig2 or SOX10. Ultrastructurally, they also harbored features reminiscent of ependymal differentiation, such as cilia. Different gene partners were fused with PLAGL1: FOXO1, EWSR1 and for the first time MAML2. The PLAGL1 FISH presented a 100% sensitivity and specificity according to RNA sequencing and DNA methylation profiling results. This cohort of supratentorial PLAGL1-fused tumors highlights: 1/ the ependymal cell origin of this new neoplastic entity; 2/ benefit of looking for a PLAGL1 fusion in supratentorial cases of non-ZFTA/non-YAP1 ependymomas; and 3/ the usefulness of PLAGL1 FISH., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
33. A comprehensive histomolecular characterization of meningioangiomatosis: Further evidence for a precursor neoplastic lesion.
- Author
-
Tauziède-Espariat A, Masliah-Planchon J, Sievers P, Sahm F, Dangouloff-Ros V, Boddaert N, Hasty L, Aboubakr O, Métais A, Chrétien F, Roux A, Pallud J, Blauwblomme T, Beccaria K, Bourdeaut F, Puget S, and Varlet P
- Abstract
Meningioangiomatosis (MAM) remains a poorly understood lesion responsible for epileptic disease. In the past, MAM was primarily described in the context of neurofibromatosis type 2 before being mainly reported sporadically. Moreover, the malformative or tumoral nature is still debated. Because a subset of MAM are associated with meningiomas, some authors argue that MAM corresponds to an infiltration pattern of these tumors. For these reasons, MAM has not been added to the World Health Organization (WHO) Classification of Central Nervous System Tumors as a specific entity. In the present study, we characterized a series of pure MAM (n = 7) and MAM associated with meningiomas (n = 4) using histopathology, immunohistochemistry, genetic (fluorescent in situ and DNA sequencing analyses), and epigenetic (DNA-methylation profiling) data. We evidenced two distinct morphological patterns: MAM with a fibroblastic-like pattern having few lesional cells, and MAM with a more cellular pattern. A subset was associated with the genetic alterations previously reported in meningiomas (such as a KMT2C mutation and a hemizygous deletion of chromosome 22q including the NF2 gene). The DNA-methylation profile, using a t-distributed stochastic neighbor embedding analysis, evidenced that MAM (pure or associated with meningiomas) clustered in a separate group from pediatric meningiomas. The present results seem to suggest that MAM represents a neoplastic lesion and encourage the further study of similar additional series so that it may be included in a future WHO classification., (© 2024 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.)
- Published
- 2024
- Full Text
- View/download PDF
34. Diffuse midline glioma invasion and metastasis rely on cell-autonomous signaling.
- Author
-
Bruschi M, Midjek L, Ajlil Y, Vairy S, Lancien M, Ghermaoui S, Kergrohen T, Verreault M, Idbaih A, de Biagi CAO Junior, Liu I, Filbin MG, Beccaria K, Blauwblomme T, Puget S, Tauziede-Espariat A, Varlet P, Dangouloff-Ros V, Boddaert N, Le Teuff G, Grill J, Montagnac G, Elkhatib N, Debily MA, and Castel D
- Subjects
- Child, Humans, Signal Transduction, Tumor Microenvironment, Brain Neoplasms pathology, Glioma pathology
- Abstract
Background: Diffuse midline gliomas (DMG) are pediatric tumors with negligible 2-year survival after diagnosis characterized by their ability to infiltrate the central nervous system. In the hope of controlling the local growth and slowing the disease, all patients receive radiotherapy. However, distant progression occurs frequently in DMG patients. Current clues as to what causes tumor infiltration circle mainly around the tumor microenvironment, but there are currently no known determinants to predict the degree of invasiveness., Methods: In this study, we use patient-derived glioma stem cells (GSCs) to create patient-specific 3D avatars to model interindividual invasion and elucidate the cellular supporting mechanisms., Results: We show that GSC models in 3D mirror the invasive behavior of the parental tumors, thus proving the ability of DMG to infiltrate as an autonomous characteristic of tumor cells. Furthermore, we distinguished 2 modes of migration, mesenchymal and ameboid-like, and associated the ameboid-like modality with GSCs derived from the most invasive tumors. Using transcriptomics of both organoids and primary tumors, we further characterized the invasive ameboid-like tumors as oligodendrocyte progenitor-like, with highly contractile cytoskeleton and reduced adhesion ability driven by crucial over-expression of bone morphogenetic pathway 7 (BMP7). Finally, we deciphered MEK, ERK, and Rho/ROCK kinases activated downstream of the BMP7 stimulation as actionable targets controlling tumor cell motility., Conclusions: Our findings identify 2 new therapeutic avenues. First, patient-derived GSCs represent a predictive tool for patient stratification in order to adapt irradiation strategies. Second, autocrine and short-range BMP7-related signaling becomes a druggable target to prevent DMG spread and metastasis., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
35. Imaging features to distinguish posterior fossa ependymoma subgroups.
- Author
-
Leclerc T, Levy R, Tauziède-Espariat A, Roux CJ, Beccaria K, Blauwblomme T, Puget S, Grill J, Dufour C, Guerrini-Rousseau L, Abbou S, Bolle S, Roux A, Pallud J, Provost C, Oppenheim C, Varlet P, Boddaert N, and Dangouloff-Ros V
- Subjects
- Child, Adult, Adolescent, Humans, Child, Preschool, Young Adult, Magnetic Resonance Imaging, Prognosis, Head, Ependymoma diagnostic imaging, Ependymoma genetics, Ependymoma pathology, Hydrocephalus
- Abstract
Objectives: Posterior fossa ependymoma group A (EPN_PFA) and group B (EPN_PFB) can be distinguished by their DNA methylation and give rise to different prognoses. We compared the MRI characteristics of EPN_PFA and EPN_PFB at presentation., Methods: Preoperative imaging of 68 patients with posterior fossa ependymoma from two centers was reviewed by three independent readers, blinded for histomolecular grouping. Location, tumor extension, tumor volume, hydrocephalus, calcifications, tissue component, enhancement or diffusion signal, and histopathological data (cellular density, calcifications, necrosis, mitoses, vascularization, and microvascular proliferation) were compared between the groups. Categorical data were compared between groups using Fisher's exact tests, and quantitative data using Mann-Whitney tests. We performed a Benjamini-Hochberg correction of the p values to account for multiple tests., Results: Fifty-six patients were categorized as EPN_PFA and 12 as EPN_PFB, with median ages of 2 and 20 years, respectively (p = 0.0008). The median EPN_PFA tumoral volume was larger (57 vs 29 cm
3 , p = 0.003), with more pronounced hydrocephalus (p = 0.002). EPN_PFA showed an exclusive central position within the 4th ventricle in 61% of patients vs 92% for EPN_PFB (p = 0.01). Intratumor calcifications were found in 93% of EPN_PFA vs 40% of EPN_PFB (p = 0.001). Invasion of the posterior fossa foramina was mostly found for EPN_PFA, particularly the foramina of Luschka (p = 0.0008). EPN_PFA showed whole and homogeneous tumor enhancement in 5% vs 75% of EPN_PFB (p = 0.0008). All mainly cystic tumors were EPN_PFB (p = 0.002). The minimal and maximal relative ADC was slightly lower in EPN_PFA (p = 0.02 and p = 0.01, respectively)., Conclusion: Morphological characteristics from imaging differ between posterior fossa ependymoma subtypes and may help to distinguish them preoperatively., Clinical Relevance Statement: This study provides a tool to differentiate between group A and group B ependymomas, which will ultimately allow the therapeutic strategy to be adapted in the early stages of patient management., Key Points: • Posterior fossa ependymoma subtypes often have different imaging characteristics. • Posterior fossa ependymomas group A are commonly median or lateral tissular calcified masses, with incomplete enhancement, affecting young children and responsible for pronounced hydrocephalus and invasion of the posterior fossa foramina. • Posterior fossa ependymomas group B are commonly median non-calcified masses of adolescents and adults, predominantly cystic, and minimally invasive, with total and homogeneous enhancement., (© 2023. The Author(s), under exclusive licence to European Society of Radiology.)- Published
- 2024
- Full Text
- View/download PDF
36. Pediatric intracranial empyema complicating otogenic and sinogenic infection.
- Author
-
Raineau M, Crowe AM, Beccaria K, Luscan R, Simon F, Roux CJ, Ferroni A, Kossorotoff M, Harroche A, Castelle M, Gatbois E, Bourgeois M, Roy M, and Blanot S
- Subjects
- Child, Humans, Retrospective Studies, Anti-Bacterial Agents therapeutic use, Empyema, Subdural diagnosis, Empyema, Subdural epidemiology, Empyema, Subdural etiology, Brain Abscess diagnostic imaging, Brain Abscess etiology, Brain Abscess therapy, Empyema
- Abstract
Objective: To describe and compare clinical and microbiological features, surgical and medical management, and outcomes of children with otogenic and sinogenic intracranial empyema (IE) in an institution with an established multidisciplinary protocol. To use the study findings to inform and update the institutional algorithm., Methods: Retrospective analysis was carried out on the electronic healthcare records of all children with oto-sinogenic IE admitted in a 5-year period., Results: A total of 76 patients were identified and treated according to an institutional protocol. Two distinct groups were identified: intracranial empyema related to otogenic infection (OI-IE, n = 36) or sinogenic infection (SI-IE, n = 40). SI-IE was seen in older children and had a significantly higher morbidity. Sub-dural IE was seen in a minority (n = 16) and only in SI-IE and required urgent collaborative ENT-neurosurgery. Extra-dural IE occurred more frequently and was seen in both SI-IE and OI-IE. No death and overall low morbidity were observed. Particularities found in SI-IE and OI-IE groups (as thrombosis, microbiology, antibiotic treatment, duration and outcome) permitted the delineation of these groups in our updated algorithm., Conclusion: The presence of a collaborative multidisciplinary protocol permits the step-wise co-ordination of care for these complex patients in our institution. All patients received prompt imaging, urgent surgical intervention, and antibiotic treatment. Microbiological identification was possible for each patient and antibiotic rationalization was permitted through use of Polymerase chain reaction (PCR) testing in cases of sterile cultures. Of note, intracranial empyema related to sinogenic infection is shown to have significantly more severe clinical presentation, a higher morbidity, and a longer duration of antibiotic therapy than that related to otogenic infection. Study findings allowed for the update and clarification of the institutional protocol, which now clearly demarcates the clinical presentation, biological evidence, radiology, surgical and medical treatments in children with oto-sinogenic IE., Competing Interests: Declaration of competing interest None., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. The utility of poly(somno)graphy in evaluating children with Chiari malformation type II before and after surgical intervention: a case series.
- Author
-
Vagianou F, Khirani S, de Saint Denis T, Beccaria K, Amaddeo A, Breton S, James S, Paternoster G, Arnaud E, Zerah M, and Fauroux B
- Subjects
- Child, Humans, Neurosurgical Procedures methods, Magnetic Resonance Imaging, Prevalence, Arnold-Chiari Malformation complications, Arnold-Chiari Malformation diagnostic imaging, Arnold-Chiari Malformation surgery, Sleep Apnea Syndromes diagnosis, Sleep Apnea Syndromes surgery, Sleep Apnea Syndromes etiology
- Abstract
Background: Children with Chiari Malformation type II (CM-II) have an increased risk of sleep apnoea. The aim of the study was to describe the management of patients with CM-II in relation to sleep apnoea syndrome, clinical symptoms and magnetic resonance imaging (MRI) findings., Case Series Presentation: The paper reports 8 consecutive patients with CM-II followed between September 2013 and April 2017. The prevalence of sleep apnoea syndrome was high with 6 out of 8 patients having mild-to-severe sleep apnoea. Patients with severe sleep apnoea syndrome (3 patients) were treated with upper airway surgery and/or noninvasive ventilation., Conclusion: Our findings highlight the importance of respiratory polygraphy in the management of patients with CM-ΙΙ. Poly(somno)graphy is recommended in the follow-up care of children with CM-II.
- Published
- 2024
- Full Text
- View/download PDF
38. CNS erythroblastic sarcoma: a potential emerging pediatric tumor type characterized by NFIA::RUNX1T1/3 fusions.
- Author
-
Tauziède-Espariat A, Lew-Derivry L, Abbou S, Métais A, Pierron G, Reynaud S, Masliah-Planchon J, Mariet C, Hasty L, Dangouloff-Ros V, Boddaert N, Csanyi M, Aline-Fardin A, Lamaison C, Chrétien F, Beccaria K, Puget S, and Varlet P
- Subjects
- Child, Preschool, Humans, Infant, Male, Middle Aged, Bone Marrow pathology, NFI Transcription Factors genetics, NFI Transcription Factors metabolism, RUNX1 Translocation Partner 1 Protein metabolism, Central Nervous System Neoplasms pathology, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute metabolism, Leukemia, Myeloid, Acute pathology, Sarcoma metabolism, Sarcoma pathology, Sarcoma, Myeloid genetics, Sarcoma, Myeloid diagnosis, Sarcoma, Myeloid metabolism
- Abstract
Erythroblastic sarcoma (ES) (previously called chloroma or granulocytic sarcoma) are rare hematological neoplams characterized by the proliferation of myeloid blasts at extramedullary sites, and primarily involve the skin and soft tissue of middle-aged adults. ES may be concomitant with or secondary to myeloid neoplasms (mostly acute myeloid leukemia (AML)) or in isolated cases (de novo) without infiltration of the bone marrow by blasts. ES share cytogenetic and molecular abnormalities with AML, including RUNX1T1 fusions. Some of these alterations seem to be correlated with particular sites of involvement. Herein, we report an isolated erythroblastic sarcoma with NFIA::RUNX1T1 located in the central nervous system (CNS) of a 3-year-old boy. Recently, two pediatric cases of CNS MS with complete molecular characterization have been documented. Like the current case, they concerned infants (2 and 3 years-old) presenting a brain tumor (pineal involvement) with leptomeningeal dissemination. Both cases also harbored a NFIA::RUNX1T3 fusion. ES constitutes a diagnostic challenge for neuropathologists because it does not express differentiation markers such as CD45, and may express CD99 which could be confused with CNS Ewing sarcoma. CD43 is the earliest pan-hematopoietic marker and CD45 is not expressed by erythroid lineage cells. E-cadherin (also a marker of erythroid precursors) and CD117 (expressed on the surface of erythroid lineage cells) constitute other immunhistochemical hallmarks of ES. The prognosis of patients with ES is similar to that of other patients with AML but de novo forms seem to have a poorer prognosis, like the current case. To conclude, pediatric ES with NFIA::RUNX1T1/3 fusions seem to have a tropism for the CNS and thus constitute a potential pitfall for neuropathologists. Due to the absence of circulating blasts and a DNA-methylation signature, the diagnosis must currently be made by highlighting the translocation and expression of erythroid markers., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
39. "Hemispheric pilocytic astrocytoma" revisited: A comprehensive clinicopathological and molecular series emphasizing their overlap with other glioneuronal tumors.
- Author
-
Mariet C, Grill J, Ajlil Y, Castel D, Dangouloff-Ros V, Boddaert N, Meurgey A, Pissaloux D, Appay R, Saffroy R, Puget S, Blauwblomme T, Beccaria K, Hasty L, Rigau V, Roujeau T, Aline-Fardin A, Chrétien F, Métais A, Varlet P, and Tauziède-Espariat A
- Subjects
- Child, Humans, DNA, 2-Methyl-4-chlorophenoxyacetic Acid, Astrocytoma pathology, Glioma genetics, Central Nervous System Neoplasms, Neoplasms, Neuroepithelial genetics, Neoplasms, Neuroepithelial pathology, Brain Neoplasms diagnostic imaging, Brain Neoplasms genetics
- Abstract
Pilocytic astrocytomas (PA) typically exhibit distinct clinical, radiological, histopathological, and genetic features. DNA-methylation profiling distinguishes PA according to their location (infratentorial, midline, hemispheric, or spinal). In the hemispheric location, distinguishing PA from glioneuronal tumors remains a common diagnostic challenge for neuropathologists. Furthermore, the current version of the DKFZ classifier seems to have difficulty separating them from gangliogliomas. In this study, after central radiological review, we identified a histopathologically defined set of PA (histPA, n = 11) and a cohort of DNA-methylation defined PA (mcPA, n = 11). Nine out of the 11 histPA matched the methylation class of hemispheric PA, whereas 2 cases were classified at the end of the study as dysembryoplastic neuroepithelial tumors. Similarly, the mcPA cohort contained tumors mainly classified as PA (7/11), but 4 cases were classified as glioneuronal. The analysis of the 16 tumors with an integrated diagnosis of PA revealed that they affect mainly children with a wide spectrum of radiological, histopathological (i.e. a predominantly diffuse growth pattern), and genetic characteristics (large range of mitogen-activated protein kinase alterations). Based on these results, we consider hemispheric PA to be different from their counterparts in other locations and to overlap with other glioneuronal tumors, reinforcing the necessity of interpreting all data to obtain an accurate diagnosis., (© The Author(s) 2024. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
40. LEF-1 immunohistochemistry, a better diagnostic biomarker than β-catenin for medulloblastoma, WNT-activated subtyping.
- Author
-
Aboubakr O, Métais A, Doz F, Saffroy R, Masliah-Planchon J, Hasty L, Beccaria K, Ayrault O, Dufour C, Varlet P, and Tauziède-Espariat A
- Subjects
- Humans, beta Catenin, Biomarkers, Immunohistochemistry, Cerebellar Neoplasms diagnosis, Medulloblastoma diagnosis
- Published
- 2024
- Full Text
- View/download PDF
41. Laser interstitial thermal therapy is effective and safe for the treatment of brain tumors in NF1 patients after cerebral revascularization for moyamoya angiopathy: a report on two cases.
- Author
-
Guida L, Beccaria K, Benichi S, Kossorotof M, Naggara O, Bourgeois M, Bourdeaut F, Abbou S, Dangouloff-Ros V, Boddaert N, and Blauwblomme T
- Abstract
Background: The co-occurrence of moyamoya vasculopathy and extra-optic pathway tumors is rare in neurofibromatosis type 1 (NF1), with only four cases described in the literature. Brain surgery in these patients may be challenging because of the risk of brain infarction after skin and dural incision. Given its percutaneous and minimally invasive nature, laser interstitial thermal therapy (LITT) is an ideal option for the treatment of brain tumors in these patients. Here, we report on two patients with NF1 and moyamoya syndrome (MMS) treated for a brain glioma with LITT, after cerebral revascularization., Cases: The first patient, with familial NF1, underwent bilateral indirect revascularization with multiple burr holes (MBH) for symptomatic MMS. Two years later, she was diagnosed with a left temporal tumor, with evidence of radiologic progression over 10 months. The second patient, also with familial NF1, developed unilateral MMS when he was 6 years old and was treated with MBH. At the age of 15 years, MRI showed a right cingular lesion, growing on serial MRIs. Both patients underwent LITT with no perioperative complications; they are progression free at 10 and 12 months, respectively, and the tumors have decreased in volume., Discussion: While the association of extra-optic neoplasm and moyamoya angiopathy is seldom reported in NF1, tumor treatment is challenging in terms of both avoiding stroke and achieving oncological control. Here, we show in 2 cases, that LITT could be a safe and effective option in these rare conditions., Competing Interests: TB is a consultant for Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2023 Guida, Beccaria, Benichi, Kossorotof, Naggara, Bourgeois, Bourdeaut, Abbou, Dangouloff-Ros, Boddaert and Blauwblomme.)
- Published
- 2023
- Full Text
- View/download PDF
42. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
- Author
-
Auffret L, Ajlil Y, Tauziède-Espariat A, Kergrohen T, Puiseux C, Riffaud L, Blouin P, Bertozzi AI, Leblond P, Blomgren K, Froelich S, Picca A, Touat M, Sanson M, Beccaria K, Blauwblomme T, Dangouloff-Ros V, Boddaert N, Varlet P, Debily MA, Grill J, and Castel D
- Subjects
- Adult, Humans, Child, Histones genetics, Proto-Oncogene Proteins B-raf genetics, Mutation genetics, Receptor, Fibroblast Growth Factor, Type 1 genetics, Brain Neoplasms diagnostic imaging, Brain Neoplasms genetics, Brain Neoplasms pathology, Glioma diagnostic imaging, Glioma genetics, Glioma pathology, Astrocytoma genetics, Central Nervous System Neoplasms
- Abstract
Diffuse midline gliomas (DMG) H3 K27-altered are incurable grade 4 gliomas and represent a major challenge in neuro-oncology. This tumour type is now classified in four subtypes by the 2021 edition of the WHO Classification of the Central Nervous System (CNS) tumours. However, the H3.3-K27M subgroup still appears clinically and molecularly heterogeneous. Recent publications reported that rare patients presenting a co-occurrence of H3.3K27M with BRAF or FGFR1 alterations tended to have a better prognosis. To better study the role of these co-driver alterations, we assembled a large paediatric and adult cohort of 29 tumours H3K27-altered with co-occurring activating mutation in BRAF or FGFR1 as well as 31 previous cases from the literature. We performed a comprehensive histological, radiological, genomic, transcriptomic and DNA methylation analysis. Interestingly, unsupervised t-distributed Stochastic Neighbour Embedding (tSNE) analysis of DNA methylation profiles regrouped BRAF
V600E and all but one FGFR1MUT DMG in a unique methylation cluster, distinct from the other DMG subgroups and also from ganglioglioma (GG) or high-grade astrocytoma with piloid features (HGAP). This new DMG subtype harbours atypical radiological and histopathological profiles with calcification and/or a solid tumour component both for BRAFV600E and FGFR1MUT cases. The analyses of a H3.3-K27M BRAFV600E tumour at diagnosis and corresponding in vitro cellular model showed that mutation in H3-3A was the first event in the oncogenesis. Contrary to other DMG, these tumours occur more frequently in the thalamus (70% for BRAFV600E and 58% for FGFR1MUT ) and patients have a longer overall survival with a median above three years. In conclusion, DMG, H3 K27 and BRAF/FGFR1 co-altered represent a new subtype of DMG with distinct genotype/phenotype characteristics, which deserve further attention with respect to trial interpretation and patient management., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
43. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
- Author
-
Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, and Koschmann C
- Subjects
- Humans, Histones genetics, Treatment Outcome, Epigenesis, Genetic, Mutation, Glioma genetics, Glioma pathology, Brain Neoplasms genetics, Brain Neoplasms pathology
- Abstract
Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle-related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction., Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293., (©2023 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
44. Mobility Assessment Using Multi-Positional MRI in Children with Cranio-Vertebral Junction Anomalies.
- Author
-
Grenier-Chartrand F, Taverne M, James S, Guida L, Paternoster G, Loiselet K, Beccaria K, Dangouloff-Ros V, Levy R, de Saint Denis T, Blauwblomme T, Khonsari RH, Boddaert N, and Benichi S
- Abstract
Objective: This study aimed to assess the relevance of using multi-positional MRI (mMRI) to identify cranio-vertebral junction (CVJ) instability in pediatric patients with CVJ anomalies while determining objective mMRI criteria to detect this condition., Material and Methods: Data from children with CVJ anomalies who underwent a mMRI between 2017 and 2021 were retrospectively reviewed. Mobility assessment using mMRI involved: (1) morphometric analysis using hierarchical clustering on principal component analysis (HCPCA) to identify clusters of patients by considering their mobility similarities, assessed through delta (Δ) values of occipito-cervical parameters measured on mMRI; and (2) morphological analysis based on dynamic geometric CVJ models and analysis of displacement vectors between flexion and extension. Receiver operating characteristics (ROC) curves were generated for occipito-cervical parameters to establish instability cut-off values. (3) Additionally, an anatomical qualitative analysis of the CVJ was performed to identify morphological criteria of instability., Results: Forty-seven patients with CVJ anomalies were included (26 females, 21 males; mean age: 10.2 years [3-18]). HCPCA identified 2 clusters: cluster №1 (stable patients, n = 39) and cluster №2 (unstable patients, n = 8). ΔpB-C2 (pB-C2 line delta) at ≥2.5 mm (AUC 0.98) and ΔBAI (Basion-axis Interval delta) ≥ 3 mm (AUC 0.97) predicted instability with 88% sensibility and 95% specificity and 88% sensitivity and 85% specificity, respectively. Geometric CVJ shape analysis differentiated patients along a continuum, from a low to a high CVJ motion that was characterized by a subluxation of C1 in the anterior direction. Qualitative analysis found correlations between instability and C2 anomalies, including fusions with C3 (body p = 0.032; posterior arch p = 0.045; inferior articular facets p = 0.012; lateral mass p = 0.029)., Conclusions: We identified a cluster of pediatric patients with CVJ instability among a cohort of CVJ anomalies that were characterized by morphometric parameters with corresponding cut-off values that could serve as objective mMRI criteria. These findings warrant further validation through prospective case-control studies.
- Published
- 2023
- Full Text
- View/download PDF
45. Imaging and multi-omics datasets converge to define different neural progenitor origins for ATRT-SHH subgroups.
- Author
-
Lobón-Iglesias MJ, Andrianteranagna M, Han ZY, Chauvin C, Masliah-Planchon J, Manriquez V, Tauziede-Espariat A, Turczynski S, Bouarich-Bourimi R, Frah M, Dufour C, Blauwblomme T, Cardoen L, Pierron G, Maillot L, Guillemot D, Reynaud S, Bourneix C, Pouponnot C, Surdez D, Bohec M, Baulande S, Delattre O, Piaggio E, Ayrault O, Waterfall JJ, Servant N, Beccaria K, Dangouloff-Ros V, and Bourdeaut F
- Subjects
- Humans, Multiomics, SMARCB1 Protein genetics, Transcription Factors genetics, Diagnostic Imaging, Hedgehog Proteins genetics, Rhabdoid Tumor genetics, Brain Neoplasms genetics, Teratoma pathology
- Abstract
Atypical teratoid rhabdoid tumors (ATRT) are divided into MYC, TYR and SHH subgroups, suggesting diverse lineages of origin. Here, we investigate the imaging of human ATRT at diagnosis and the precise anatomic origin of brain tumors in the Rosa26-Cre
ERT2 ::Smarcb1flox/flox model. This cross-species analysis points to an extra-cerebral origin for MYC tumors. Additionally, we clearly distinguish SHH ATRT emerging from the cerebellar anterior lobe (CAL) from those emerging from the basal ganglia (BG) and intra-ventricular (IV) regions. Molecular characteristics point to the midbrain-hindbrain boundary as the origin of CAL SHH ATRT, and to the ganglionic eminence as the origin of BG/IV SHH ATRT. Single-cell RNA sequencing on SHH ATRT supports these hypotheses. Trajectory analyses suggest that SMARCB1 loss induces a de-differentiation process mediated by repressors of the neuronal program such as REST, ID and the NOTCH pathway., (© 2023. Springer Nature Limited.)- Published
- 2023
- Full Text
- View/download PDF
46. VRK3 depletion induces cell cycle arrest and metabolic reprogramming of pontine diffuse midline glioma - H3K27 altered cells.
- Author
-
Menez V, Kergrohen T, Shasha T, Silva-Evangelista C, Le Dret L, Auffret L, Subecz C, Lancien M, Ajlil Y, Vilchis IS, Beccaria K, Blauwblomme T, Oberlin E, Grill J, Castel D, and Debily MA
- Abstract
We previously identified VRK3 as a specific vulnerability in DMG-H3K27M cells in a synthetic lethality screen targeting the whole kinome. The aim of the present study was to elucidate the mechanisms by which VRK3 depletion impact DMG-H3K27M cell fitness. Gene expression studies after VRK3 knockdown emphasized the inhibition of genes involved in G1/S transition of the cell cycle resulting in growth arrest in G1. Additionally, a massive modulation of genes involved in chromosome segregation was observed, concomitantly with a reduction in the level of phosphorylation of serine 10 and serine 28 of histone H3 supporting the regulation of chromatin condensation during cell division. This last effect could be partly due to a concomitant decrease of the chromatin kinase VRK1 in DMG following VRK3 knockdown. Furthermore, a metabolic switch specific to VRK3 function was observed towards increased oxidative phosphorylation without change in mitochondria content, that we hypothesized would represent a cell rescue mechanism. This study further explored the vulnerability of DMG-H3K27M cells to VRK3 depletion suggesting potential therapeutic combinations, e.g. with the mitochondrial ClpP protease activator ONC201., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Menez, Kergrohen, Shasha, Silva-Evangelista, Le Dret, Auffret, Subecz, Lancien, Ajlil, Vilchis, Beccaria, Blauwblomme, Oberlin, Grill, Castel and Debily.)
- Published
- 2023
- Full Text
- View/download PDF
47. Predicting endoscopic third ventriculostomy success in pediatric shunt dysfunction: a monocentric retrospective case series of 70 consecutive children, systematic review, and meta-analysis.
- Author
-
Guida L, Grenier-Chartrand F, Benichi S, James S, Paternoster G, Bourgeois M, Dangouloff-Ros V, Messina A, Boddaert N, Puget S, Beccaria K, and Blauwblomme T
- Subjects
- Child, Child, Preschool, Humans, Infant, Retrospective Studies, Treatment Outcome, Ventriculostomy adverse effects, Hydrocephalus diagnostic imaging, Hydrocephalus etiology, Hydrocephalus surgery, Neuroendoscopy adverse effects, Third Ventricle diagnostic imaging, Third Ventricle surgery
- Abstract
Objective: The outcome of endoscopic third ventriculostomy (ETV) in children who had previously received shunts and who were experiencing shunt dysfunction is still discussed in terms of efficacy (success rate from 40% to 80%) and safety (0%-32.5% of complications). Reported predictive factors of secondary ETV failure are age, early onset of hydrocephalus, and prematurity. The best surgical strategy in the different subgroups of patients with shunt dysfunction is still debated. Therefore, the authors aimed to identify subgroups of patients in whom shunt treatment was associated with favorable outcome of ETV, to define the role of ETV in patients with global rostral midbrain dysfunction syndrome., Methods: This study was a monocentric retrospective case series and a meta-analysis of children who had previously received shunts and who underwent secondary ETV for shunt dysfunction between 2012 and 2022. Clinical and MRI features were examined, along with surgical outcome, etiology of hydrocephalus, and preoperative ETV Success Score. Univariate and multivariate analyses were performed to find predictors of outcome of secondary ETV. Youden's J index was calculated on age distribution to find an optimal age cutoff. Systematic review of the literature and a meta-analysis were performed according to the PRISMA statement., Results: Seventy consecutive patients were included. The overall success rate of secondary ETV was 63%. Primary obstructive hydrocephalus, age ≥ 36 months, and the presence of aqueductal obstruction were predictors of ETV success. Multivariate analysis found that age < 36 months, primary inflammatory hydrocephalus, and presence of fourth ventricular obstruction were associated with ETV failure. All patients with global rostral midbrain dysfunction syndrome experienced clinical and radiological improvement after ETV. The meta-analysis showed that postinflammatory etiology and age < 36 months were predictors of ETV failure., Conclusions: ETV is safe and effective for children with obstructive hydrocephalus experiencing shunt dysfunction, notably in cases of primary obstructive hydrocephalus with aqueductal stenosis, and among children whose age was ≥ 36 months who had postinflammatory hydrocephalus.
- Published
- 2023
- Full Text
- View/download PDF
48. The Management of Hydrocephalus in Midline Posterior Fossa Cystic Collections: Surgical Outcome From a Retrospective Single-Center Case Series of 54 Consecutive Pediatric Patients.
- Author
-
Guida L, Benichi S, Bourgeois M, Paternoster G, James S, De Saint Denis T, Dangouloff Ros V, Beccaria K, and Blauwblomme T
- Subjects
- Humans, Child, Retrospective Studies, Cerebellum, Magnetic Resonance Imaging methods, Cranial Fossa, Posterior diagnostic imaging, Cranial Fossa, Posterior surgery, Dandy-Walker Syndrome complications, Dandy-Walker Syndrome diagnostic imaging, Dandy-Walker Syndrome surgery, Hydrocephalus diagnostic imaging, Hydrocephalus etiology, Hydrocephalus surgery, Arachnoid Cysts
- Abstract
Background: Hydrocephalus frequently occurs with midline posterior fossa cystic collections. The classification of this heterogeneous group of developmental anomalies, including Dandy-Walker malformation, persisting Blake's pouch, retrocerebellar arachnoid cysts, and mega cisterna magna, is subject of debate. The absence of diagnostic criteria is confusing regarding the ideal management of PFCC-related hydrocephalus., Objective: To decipher the surgical strategy for the treatment of children with PFCC-related hydrocephalus through a retrospective analysis of the surgical outcome driven by their clinical and radiological presentation., Methods: This study enrolled patients operated of symptomatic PFCC-related hydrocephalus. Clinical and MRI features were examined, as well as the surgical outcome. Unbiased subgroup classification of the patients was performed with multiple component analysis as a function of imaging characteristics and hierarchical clustering on principal component. Outcome was assessed with binomial logistic regression and Kaplan-Meier analysis., Results: Fifty-four patients were included between 2007 and 2021. Multiple component analysis suggested that cerebellar and vermian hypoplasia, vermian rotation, basal-tentorial angle, and fastigial angle were strongly correlated. Hierarchical clustering and the distribution of the patients in the bidimensional plot showed the clear segregation of 3 major clusters, which correlated with the radiological diagnosis ( P < .01). Binomial logistic regression and survival analysis showed that endoscopic third ventriculostomy was an effective treatment for patients with persisting Blake's pouch, while failing to control hydrocephalus in most of patients with Dandy-Walker malformation., Conclusion: Preoperative MRI in patients with PFCC-related hydrocephalus is essential to better define the diagnosis. The choice of treatment strategy notably relies on correct radiological diagnosis., (Copyright © Congress of Neurological Surgeons 2023. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
49. A comprehensive analysis of infantile central nervous system tumors to improve distinctive criteria for infant-type hemispheric glioma versus desmoplastic infantile ganglioglioma/astrocytoma.
- Author
-
Tauziède-Espariat A, Beccaria K, Dangouloff-Ros V, Sievers P, Meurgey A, Pissaloux D, Appay R, Saffroy R, Grill J, Mariet C, Bourdeaut F, Hasty L, Métais A, Chrétien F, Blauwblomme T, Puget S, Boddaert N, and Varlet P
- Subjects
- Humans, Proto-Oncogene Proteins B-raf genetics, Retrospective Studies, In Situ Hybridization, Fluorescence, Protein-Tyrosine Kinases, Proto-Oncogene Proteins genetics, DNA-Binding Proteins genetics, Transcription Factors genetics, RNA-Binding Proteins, Ganglioglioma genetics, Ganglioglioma pathology, Brain Neoplasms pathology, Astrocytoma genetics, Astrocytoma pathology, Central Nervous System Neoplasms, Neoplasms, Neuroepithelial, Ependymoma
- Abstract
Recent epigenomic analyses have revealed the existence of a new DNA methylation class (MC) of infant-type hemispheric glioma (IHG). Like desmoplastic infantile ganglioglioma/astrocytoma (DIG/DIA), these tumors mainly affect infants and are supratentorial. While DIG/DIA is characterized by BRAF or RAF1 alterations, IHG has been shown to have receptor tyrosine kinase (RTK) gene fusions (ALK, ROS1, NTRK1/2/3, and MET). However, in this rapidly evolving field, a more comprehensive analysis of infantile glial/glioneuronal tumors including clinical, radiological, histopathological, and molecular data is needed. Here, we retrospectively investigated data from 30 infantile glial/glioneuronal tumors, consecutively compiled from our center. They were analyzed by two experienced pediatric neuroradiologists in consensus, without former knowledge of the molecular data. We also performed a comprehensive clinical, and histopathological examination (including molecular evaluation by next-generation sequencing, RNA sequencing, and fluorescence in situ hybridization [FISH] analyses), as well as DNA methylation profiling for the samples having sufficient material available. The integrative histopathological, genetic, and epigenetic analyses, including t-distributed stochastic neighbor embedding (t-SNE) analyses segregated tumors into 10 DIG/DIA (33.3%), six IHG (20.0%), three gangliogliomas (10.0%), two pleomorphic xanthoastrocytomas (6.7%), two pilocytic astrocytomas (6.7%), two supratentorial ependymomas, ZFTA fusion-positive (6.7%), two supratentorial ependymomas, YAP1 fusion-positive (6.7%), two embryonal tumors with PLAGL2-family amplification (6.7%), and one diffuse low-grade glioma, MAPK-pathway altered. This study highlights the significant differential features, in terms of histopathology (leptomeningeal infiltration, intense desmoplasia and ganglion cells in DIG/DIA and necrosis, microvascular proliferation, and siderophages in IHG), and radiology between DIG/DIA and IHG. Moreover, these results are consistent with the literature data concerning the molecular dichotomy (BRAF/RAF1 alterations vs. RTK genes' fusions) between DIG/DIA and IHG. This study characterized histopathologically and radiologically two additional cases of the novel embryonal tumor characterized by PLAGL2 gene amplification., (© 2023 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.)
- Published
- 2023
- Full Text
- View/download PDF
50. Diagnostic accuracy of a minimal immunohistochemical panel in at/rt molecular subtyping, correlated to dna-methylation profiling.
- Author
-
Tauziède-Espariat A, Masliah-Planchon J, Andrianteranagna M, Sievers P, Sahm F, von Deimling A, Hasty L, Delattre O, Beccaria K, Métais A, Chrétien F, Varlet P, and Bourdeaut F
- Subjects
- Humans, DNA Methylation, Immunohistochemistry
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.